Teleflex (TFX) 10-Q 3 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jul. 02, 2017	Jul. 31, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jul. 2, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Trading Symbol	TFX
Entity Registrant Name	TELEFLEX INCORPORATED
Entity Central Index Key	96,943
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		45,037,418

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Income Statement [Abstract]
Net revenues	$ 528,613	$ 473,553	$ 1,016,494	$ 898,446
Cost of goods sold	238,329	217,154	470,650	416,900
Gross profit	290,284	256,399	545,844	481,546
Selling, general and administrative expenses	158,934	142,983	322,903	279,331
Research and development expenses	20,278	15,472	38,105	27,825
Restructuring charges	870	(119)	13,815	9,849
Gain on sale of assets	0	(378)	0	(1,397)
Income from continuing operations before interest, loss on extinguishment of debt and taxes	110,202	98,441	171,021	165,938
Interest expense	19,894	11,907	37,620	25,691
Interest income	(161)	(129)	(330)	(209)
Loss on extinguishment of debt	11	19,261	5,593	19,261
Income from continuing operations before taxes	90,458	67,402	128,138	121,195
Taxes on income from continuing operations	12,095	8,007	9,426	10,620
Income from continuing operations	78,363	59,395	118,712	110,575
Operating income (loss) from discontinued operations	(566)	6	(848)	(376)
Benefit on income (loss) from discontinued operations	(206)	(187)	(309)	(257)
Income (loss) from discontinued operations	(360)	193	(539)	(119)
Net income	78,003	59,588	118,173	110,456
Less: Income from continuing operations attributable to noncontrolling interest	0	285	0	464
Net income attributable to common shareholders	$ 78,003	$ 59,303	$ 118,173	$ 109,992
Basic:
Income from continuing operations (in dollars per share)	$ 1.74	$ 1.36	$ 2.64	$ 2.58
Income (loss) from discontinued operations (in dollars per share)	(0.01)	0	(0.01)	0
Net income (in dollars per share)	1.73	1.36	2.63	2.58
Diluted:
Income from continuing operations (in dollars per share)	1.67	1.25	2.54	2.29
Loss from discontinued operations (in dollars per share)	0	0.01	(0.01)	0
Net income (in dollars per share)	1.67	1.26	2.53	2.29
Dividends per share (in dollars per share)	$ 0.34	$ 0.34	$ 0.68	$ 0.68
Weighted average common shares outstanding
Basic (in shares)	44,996	43,549	44,945	42,598
Diluted (in shares)	46,818	47,246	46,716	48,014
Amounts attributable to common shareholders:
Income from continuing operations, net of tax	$ 78,363	$ 59,110	$ 118,712	$ 110,111
Income (loss) from discontinued operations, net of tax	(360)	193	(539)	(119)
Net income	$ 78,003	$ 59,303	$ 118,173	$ 109,992

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 78,003	$ 59,588	$ 118,173	$ 110,456
Other comprehensive income (loss), net of tax:
Foreign currency translation, net of tax of $(11,392), $1,526, $(18,481), and $(2,651) for the three and six month periods, respectively	65,685	(9,237)	112,667	11,218
Pension and other postretirement benefit plans adjustment, net of tax of $(465), $(641), $(997) $(1,270) for the three and six month periods, respectively	704	1,246	1,594	2,484
Derivatives qualifying as hedges, net of tax of $(615), $984, $(1,170), and $605 for the three and six month periods, respectively	3,433	(496)	5,161	984
Other comprehensive income (loss), net of tax:	69,822	(8,487)	119,422	14,686
Comprehensive income	147,825	51,101	237,595	125,142
Less: comprehensive income attributable to noncontrolling interest	0	239	0	397
Comprehensive income attributable to common shareholders	$ 147,825	$ 50,862	$ 237,595	$ 124,745

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Statement of Comprehensive Income [Abstract]
Foreign currency translation, tax	$ (11,392)	$ 1,526	$ (18,481)	$ (2,651)
Pension and other postretirement benefits plans adjustment, tax	(465)	(641)	(997)	(1,270)
Derivatives qualifying as hedges, tax	$ (615)	$ 984	$ (1,170)	$ 605

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jul. 02, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 676,214	$ 543,789
Accounts receivable, net	303,702	271,993
Inventories, net	368,526	316,171
Prepaid expenses and other current assets	47,298	40,382
Prepaid taxes	11,878	8,179
Assets held for sale	0	2,879
Total current assets	1,407,618	1,183,393
Property, plant and equipment, net	369,301	302,899
Goodwill	1,854,076	1,276,720
Intangible assets, net	1,612,904	1,091,663
Deferred tax assets	1,963	1,712
Other assets	44,162	34,826
Total assets	5,290,024	3,891,213
Current liabilities
Current borrowings	112,039	183,071
Accounts payable	81,973	69,400
Accrued expenses	85,050	65,149
Current portion of contingent consideration	584	587
Payroll and benefit-related liabilities	78,951	82,679
Accrued interest	5,294	10,450
Income taxes payable	3,438	7,908
Other current liabilities	8,722	8,402
Total current liabilities	376,051	427,646
Long-term borrowings	1,887,716	850,252
Deferred tax liabilities	468,034	271,377
Pension and postretirement benefit liabilities	128,335	133,062
Noncurrent liability for uncertain tax positions	18,378	17,520
Other liabilities	52,981	52,015
Total liabilities	2,931,495	1,751,872
Commitments and contingencies
Convertible notes - redeemable equity component	0	1,824
Mezzanine equity	0	1,824
Total shareholders' equity	2,358,529	2,137,517
Total liabilities and shareholders' equity	$ 5,290,024	$ 3,891,213

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016
Cash flows from operating activities of continuing operations:
Net income	$ 118,173	$ 110,456
Adjustments to reconcile net income to net cash provided by operating activities:
Loss from discontinued operations	539	119
Depreciation expense	28,084	26,609
Amortization expense of intangible assets	41,375	31,397
Amortization expense of deferred financing costs and debt discount	2,825	6,554
Loss on extinguishment of debt	5,593	19,261
Gain on sale of assets	0	(1,397)
Fair value step up of acquired inventory sold	10,442	0
Changes in contingent consideration	(237)	1,242
Stock-based compensation	9,534	7,949
Deferred income taxes, net	(8,779)	(1,292)
Other	(3,300)	(1,970)
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	5,071	(10,237)
Inventories	(12,187)	(3,284)
Prepaid expenses and other current assets	4	238
Accounts payable and accrued expenses	6,541	(3,500)
Income taxes receivable and payable, net	(5,988)	(657)
Net cash provided by operating activities from continuing operations	197,690	181,488
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(36,833)	(19,535)
Proceeds from sale of assets	6,332	3,985
Payments for businesses and intangibles acquired, net of cash acquired	(993,459)	(3,117)
Net cash used in investing activities from continuing operations	(1,023,960)	(18,667)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	1,194,500	665,000
Reduction in borrowings	(228,273)	(656,479)
Debt extinguishment, issuance and amendment fees	(19,114)	(8,182)
Net proceeds from share based compensation plans and the related tax impacts	1,305	6,593
Payments for contingent consideration	(153)	(133)
Dividends paid	(30,590)	(28,998)
Net cash provided by (used in) financing activities from continuing operations	917,675	(22,199)
Cash flows from discontinued operations:
Net cash used in operating activities	(961)	(1,183)
Net cash used in discontinued operations	(961)	(1,183)
Effect of exchange rate changes on cash and cash equivalents	41,981	(1,315)
Net increase in cash and cash equivalents	132,425	138,124
Cash and cash equivalents at the beginning of the period	543,789	338,366
Cash and cash equivalents at the end of the period	676,214	476,490
Non cash financing activities of continuing operations:
Settlement and exchange of convertible notes with common or treasury stock	983	35,197
Acquisition of treasury stock associated with settlement and exchange of convertible note hedge and warrant agreements	$ 19,361	$ 85,895

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock
Beginning Balance at Dec. 31, 2015					$ (371,124)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 110,456
Other comprehensive income	14,686
Ending Balance at Jun. 26, 2016					(356,371)
Beginning Balance (in shares) at Dec. 31, 2016		45,814				1,741
Beginning Balance at Dec. 31, 2016	2,137,517	$ 45,814	$ 506,800	$ 2,194,593	(438,717)	$ (170,973)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	118,173			118,173
Cash dividends ($0.68 per share)	(30,590)			(30,590)
Other comprehensive income	119,422				119,422
Settlements of convertible notes (in shares)		928				1
Settlements of convertible notes	4,848	$ 928	3,865			$ 55
Settlements of note hedges associated with convertible notes and warrants (in shares)						119
Settlements of note hedges associated with convertible notes and warrants	3		19,361			$ (19,358)
Shares issued under compensation plans (in shares)		(80)				(46)
Shares issued under compensation plans	9,068	$ 80	6,717			$ 2,271
Deferred compensation (in shares)						(2)
Deferred compensation	88					$ 88
Ending Balance (in shares) at Jul. 02, 2017		46,822				1,813
Ending Balance at Jul. 02, 2017	$ 2,358,529	$ 46,822	$ 536,743	$ 2,282,176	$ (319,295)	$ (187,917)

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Statement of Stockholders' Equity [Abstract]
Dividends per share (in dollars per share)	$ 0.34	$ 0.34	$ 0.68	$ 0.68

Basis of presentation

Basis of presentation	6 Months Ended
	Jul. 02, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Note 1 — Basis of presentation The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our,” “Teleflex” and the “Company”) are prepared on the same basis as its annual consolidated financial statements. In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair statement of financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and with Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year. In accordance with applicable accounting standards, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in the Company's annual consolidated financial statements. The year-end condensed consolidated balance sheet data was derived from the Company's audited financial statements, but, as permitted by Rule 10-01 of Regulation S-X, does not include all disclosures required by GAAP for complete financial statements. Accordingly, the Company's quarterly condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2016 .

New accounting standards

New accounting standards	6 Months Ended
	Jul. 02, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	Note 2 — New accounting standards In May 2014, the Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. This new guidance, collectively with related guidance provided by the FASB, is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance is effective for annual periods beginning after December 15, 2017 and interim periods within those years. The Company will adopt this standard in the first quarter 2018 and expects to use the modified retrospective method of adoption by recognizing the cumulative effect of adopting this guidance as an adjustment to the Company's opening balance of retained earnings. Although the Company's evaluation of this guidance is ongoing, the Company's preliminary assessment indicates that the adoption of this guidance will not have a material impact on the Company’s results of operations, cash flows and financial position. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements; the guidance provides certain practical expedients. The Company is currently evaluating this guidance to determine its impact on the Company’s results of operations, cash flows and financial position. In March 2016, the FASB issued new guidance designed to simplify several aspects of the accounting for share-based payment transactions, including, among other things, guidance related to accounting for income taxes, modification of the criteria for classification of awards as either equity awards or liability awards where an employer withholds shares from an employee's share-based award for tax withholding purposes, and classification on the statement of cash flows of cash payments to a tax authority by an employer that withholds shares from an employee's award for tax withholding purposes. The Company adopted this guidance as of January 1, 2017. The Company has applied the new guidance requiring recognition of excess tax deficiencies and tax benefits in the income statement, rather than in additional paid-in-capital, as previously required. The adoption of the new standard increased net income and cash flows from operating activities by $1.1 million and $4.5 million ( $0.02 and $0.09 diluted earnings per share) for the three and six months ended July 2, 2017 , respectively. The Company will continue to estimate forfeitures of share-based awards at the time of grant, rather than recognize actual forfeitures as they occur, as permitted under the new guidance. In August 2016, the FASB issued new guidance with regard to eight specific issues pertaining to the classification of certain cash receipts and cash payments within the statement of cash flows. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted. The new guidance should generally be adopted using a retrospective transition method for each period presented. Although the Company's evaluation of this guidance is ongoing, the Company's preliminary assessment indicates that the adoption of this guidance will not have a material impact on the Company's cash flows. In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The guidance is effective for annual periods beginning after December 15, 2017, and early adoption is permitted as of the beginning of an annual reporting period. The guidance should be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the annual period of adoption. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated financial position or results of operations. In January 2017, the FASB issued new guidance to clarify the definition of a “business,” with the objective of assisting entities in evaluating whether a transaction should be accounted for as an acquisition (or disposal) of assets or as an acquisition of a business. The definition of a business affects many areas of accounting, including acquisitions, disposals, goodwill and consolidation. The guidance generally defines a business as an integrated set of activities and assets (collectively referred to as a “set”) that is capable of being conducted and managed for the purpose of providing a return to investors or other owners, members, or participants. The guidance further provides that, to be considered a business, a set must meet specified requirements. However, the guidance also states that, if substantially all of the fair value of gross assets acquired (subject to specified exceptions) is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not considered a business and no further analysis is required. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted under specified circumstances. In January 2017, the FASB issued guidance to simplify the quantitative test for goodwill impairment. Under current guidance, if a reporting unit’s carrying value exceeds its fair value, the entity must determine the implied value of goodwill. This determination is made by deducting the fair value of a reporting unit’s identifiable assets and liabilities from the fair value of the reporting unit as a whole as if the reporting unit had just been acquired. Under the new guidance, a determination of the implied value of goodwill will no longer be required; a goodwill impairment will be equal to the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The revised guidance is effective for fiscal years, and any interim goodwill impairment tests within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated financial position or results of operations. In March 2017, the FASB issued new guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The new guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017 and generally is required to be applied retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated results of operations. In May 2017, the FASB issued new guidance to provide clarity and reduce diversity of practice as to when an entity should account for the effects of a modification of the terms and conditions of a share-based payment award. The new guidance generally provides that modification accounting is to be applied unless the fair value (or, if applicable, calculated or intrinsic value), vesting conditions and classification as an equity instrument or liability instrument of the award are the same as was the case prior to the modification. The new guidance does not change the guidance regarding the implementation of modification accounting, if required. The new guidance is effective for reporting periods beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated results of operations. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the Company’s results of operations, cash flows or financial position.

Acquisitions

Acquisitions	6 Months Ended
	Jul. 02, 2017
Business Combinations [Abstract]
Acquisitions	Note 3 — Acquisitions The Company made two acquisitions during 2017, both of which were accounted for as business combinations. Pyng On April 3, 2017, the Company completed the acquisition of Pyng Medical Corp ("Pyng"), a medical device company that develops and markets sternal intraosseous infusion products, which complement the Company's anesthesia product portfolio. The Company acquired all of the issued and outstanding common shares of Pyng utilizing available cash. The aggregate consideration was approximately $17.9 million , net of cash acquired. The assets acquired include goodwill and finite-lived intangible assets (primarily intellectual property and customer lists) of $13.0 million and $5.5 million , respectively. The goodwill resulting from the acquisition primarily reflects synergies currently expected to be realized from the integration of the acquired business. Vascular Solutions On February 17, 2017, the Company completed the acquisition of Vascular Solutions, Inc. (“Vascular Solutions”) pursuant to a merger transaction. Vascular Solutions is a medical device company that develops and markets products for use in minimally invasive coronary and peripheral vascular procedures. In connection with the merger, subject to specified exclusions, each share of common stock of Vascular Solutions (each, a "Share" and collectively, the “Shares”) was converted into the right to receive $56.00 per Share in cash, without interest and subject to applicable withholding tax. In addition, each outstanding option or similar right to purchase Shares issued under the Vascular Solutions’ Stock Option and Stock Award Plan (the "Company Options") was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the acquisition and (ii) the excess, if any, of $56.00 over the exercise price of such Company Option. The aggregate consideration paid by the Company in connection with the merger was approximately $975.5 million , net of cash acquired. For the six months ended July 2, 2017 the Company incurred $8.2 million in transaction expenses associated with the Vascular Solutions acquisition, which are included in selling, general and administrative expenses in the condensed consolidated statement of income. For the three months ended July 2, 2017 , the Company recorded post acquisition revenue and operating profit of $45.0 million and $3.3 million , respectively, related to Vascular Solutions. For the six months ended July 2, 2017 , the Company recorded post acquisition revenue and operating loss of 66.7 million and 11.6 million , respectively. Financial information of Vascular Solutions is presented within the "All Other" category in the Company's presentation of segment information. The Vascular Solutions acquisition was financed utilizing borrowings under the Amended and Restated Credit Agreement, dated January 20, 2017 (the "Credit Agreement"), which is described in Note 7. The following table presents the purchase price allocation among the assets acquired and liabilities assumed with respect to the Vascular Solutions acquisition: (Dollars in thousands) Assets Current assets $ 63,867 Property, plant and equipment 46,616 Intangible assets 539,250 Goodwill 522,614 Other assets 728 Total assets acquired 1,173,075 Less: Current liabilities 15,079 Deferred tax liabilities 182,472 Liabilities assumed 197,551 Net assets acquired $ 975,524 The Company is continuing to evaluate the initial purchase price allocations, and further adjustments may be necessary as a result of the Company's assessment of additional information related to the fair values of the assets acquired and liabilities assumed, primarily deferred tax liabilities, certain intangible assets and goodwill. The goodwill resulting from the Vascular Solution acquisition primarily reflects synergies currently expected to be realized from the integration of the acquired businesses. The following table sets forth the components of identifiable intangible assets acquired and the ranges of the useful lives as of the date of the Vascular Solutions acquisition: Fair value Useful life range (Dollars in thousands) (Years) Intellectual property 248,200 10- 20 In-process research and development ("IPR&D") 15,600 Indefinite Trade names 16,650 20 Customer lists 258,800 25 Pro forma combined financial information The following unaudited pro forma combined financial information for the three and six months ended July 2, 2017 and June 26, 2016 , respectively, gives effect to the Vascular Solutions acquisition as if it was completed at the beginning of the earliest period presented. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company. Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Dollars and shares in thousands, except per share) Net revenue $ 528,613 $ 514,574 $ 1,039,318 $ 978,697 Net income $ 79,221 $ 59,352 $ 128,302 $ 77,252 Basic earnings per common share: Net income $ 1.76 $ 1.36 $ 2.85 $ 1.81 Diluted earnings per common share: Net income $ 1.69 $ 1.26 $ 2.75 $ 1.61 Weighted average common shares outstanding: Basic 44,996 43,549 44,945 42,598 Diluted 46,818 47,246 46,716 48,014 The unaudited pro forma combined financial information presented above includes the accounting effects of the Vascular Solutions business combination, including amortization charges from acquired intangible assets, adjustments for depreciation of property plant and equipment, interest expense, the revaluation of inventory and the related tax effects. The unaudited pro forma financial information includes non-recurring charges specifically related to the Vascular Solutions acquisition and interest expense associated with a bridge loan facility that was put in place to, among other things, assist the Company in financing the acquisition of Vascular Solutions. The unaudited pro forma combined financial information for the three and six months ended June 26, 2016 reflects the historical results of Vascular Solutions for its three and six month ended June 30, 2016, respectively, and the effects of the pro forma adjustments listed above. 2016 acquisitions The Company made the following acquisitions during 2016 (the "2016 acquisitions"), which, with the exception of its acquisition of the outstanding noncontrolling interest in Teleflex Medical Private Limited, were accounted for as business combinations: • On September 2, 2016, the Company acquired certain assets of CarTika Medical, Inc., ("CarTika"), an original equipment manufacturer (OEM) of catheters and other medical devices that complement the Company's OEM product portfolio. • On July 1, 2016, the Company, which previously owned a 74% controlling interest in its Indian affiliate, Teleflex Medical Private Limited, acquired the remaining 26% ownership interest from the noncontrolling shareholders. Teleflex Medical Private Limited is part of the Company's Asia reportable operating segment. As this acquisition did not result in a change in the Company's control of the entity, the Company recognized the $7.5 million excess of the purchase price of the noncontrolling interest over its carrying value as equity. • During the second quarter 2016, the Company acquired certain assets of two medical device and supplies distributors in New Zealand. The aggregate purchase price paid in connection with the 2016 acquisitions was $22.8 million . The results of operations of the acquired businesses and assets are included in the condensed consolidated statements of income from their respective acquisition dates. Pro forma information is not presented, as the operations of the acquired businesses are not significant to the overall operations of the Company.

Restructuring charges

Restructuring charges	6 Months Ended
	Jul. 02, 2017
Restructuring and Related Activities [Abstract]
Restructuring charges	Note 4 — Restructuring charges The following tables provide information regarding restructuring charges recognized by the Company for the three and six months ended July 2, 2017 and June 26, 2016 : Three Months Ended July 2, 2017 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2017 Vascular Solutions integration program $ 370 $ — $ — $ 34 $ 404 2017 EMEA restructuring program (584 ) — — — (584 ) 2016 Footprint realignment plan 286 10 (4 ) 99 391 2014 Footprint realignment plan (121 ) 14 — (7 ) (114 ) Other restructuring programs (1) 661 11 79 22 773 Total restructuring charges $ 612 $ 35 $ 75 $ 148 $ 870 Three Months Ended June 26, 2016 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2016 Footprint realignment plan $ (279 ) $ — $ — $ 286 $ 7 2015 Restructuring programs (442 ) 55 115 25 (247 ) 2014 Footprint realignment plan 112 — — 9 121 Total restructuring charges $ (609 ) $ 55 $ 115 $ 320 $ (119 ) Six Months Ended July 2, 2017 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2017 Vascular Solutions integration program $ 4,853 $ — $ — $ 34 $ 4,887 2017 EMEA restructuring program 6,536 — — — 6,536 2016 Footprint realignment plan 825 22 (75 ) 129 901 2014 Footprint realignment plan 182 14 — 1 197 Other restructuring programs (1) 965 58 209 62 1,294 Total restructuring charges $ 13,361 $ 94 $ 134 $ 226 $ 13,815 Six Months Ended June 26, 2016 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2016 Footprint realignment plan $ 10,068 $ — $ — $ 286 $ 10,354 2015 Restructuring programs (399 ) 178 93 118 (10 ) 2014 Footprint realignment plan (426 ) — — 11 (415 ) Other restructuring programs (2) — — (86 ) 6 (80 ) Total restructuring charges $ 9,243 $ 178 $ 7 421 $ 9,849 (1) Other restructuring programs include the 2017 Pyng Integration program, the 2016 Other Restructuring programs , the 2015 Restructuring programs, and the 2014 European Restructuring plan. The Company committed to the 2017 Pyng Integration program, which relates to the integration of Pyng into Teleflex, during the second quarter 2017. For a description of the 2015 Restructuring programs, see Note 4 to the Company’s consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2016. (2) Other restructuring programs includes the 2014 European Restructuring Plan, the Other 2014 restructuring programs, the 2013 Restructuring programs and the LMA restructuring program. For a description of these plans, see Note 4 to the Company’s consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2016. 2017 Vascular Solutions Integration Program During the first quarter 2017, the Company committed to a restructuring program related to the integration of Vascular Solutions into Teleflex. The Company initiated the program in the first quarter 2017 and expects the program to be substantially completed by the end of the second quarter 2018. The Company estimates that it will record aggregate pre-tax restructuring charges of $6.0 million to $7.5 million related to this program, of which $4.5 million to $5.3 million will constitute termination benefits, while $1.5 million to $2.2 million will relate to other exit costs, including employee relocation and outplacement costs. Additionally, the Company expects to incur $2.5 million to $3.0 million of restructuring related charges consisting primarily of retention bonuses offered to certain employees expected to remain with the Company after completion of the program. All of these charges will result in future cash outlays. 2017 EMEA Restructuring Program During the first quarter 2017, the Company committed to a restructuring program to centralize certain administrative functions in Europe. The program commenced in the second quarter 2017 and is expected to be substantially completed by the end of 2018. The Company estimates that it will record aggregate pre-tax restructuring charges of $7.1 million to $8.5 million related to this program, almost all of which constitute termination benefits, and all of which will result in future cash outlays. 2016 Other Restructuring Programs During 2016, the Company committed to programs designed to improve operating efficiencies and reduce costs. The programs involve the consolidation of certain global administrative functions and manufacturing operations. The programs commenced in the second half of 2016 and are expected to be substantially complete by the end of the first quarter 2018. The Company estimates that it will record aggregate pre-tax charges of $3.8 million to $4.7 million related to these programs, substantially all of which constitute termination benefits that will result in future cash outlays. Additionally, the Company expects to incur approximately $1.5 million of accelerated depreciation and other costs directly related to these programs and anticipates these costs will be recognized in cost of goods sold, of which approximately $1.0 million is expected to result in future outlays. As of July 2, 2017 , the Company has a restructuring reserve of $1.2 million related to these programs. 2016 Footprint Realignment Plan In 2016, the Company initiated a restructuring plan (the “2016 footprint realignment plan") designed to reduce costs, improve operating efficiencies and enhance the Company’s long term competitive position. The plan involves the relocation of certain manufacturing operations, the relocation and outsourcing of certain distribution operations and a related workforce reduction at certain of the Company's facilities. These actions commenced in the first quarter of 2016 and are expected to be substantially completed by the end of 2018. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2016 footprint realignment plan of between approximately $34 million to $44 million , of which an estimated $27 million to $31 million are expected to result in future cash outlays. Most of these charges, and the related cash outlays, are expected to be made prior to the end of 2018. In addition to the restructuring charges shown in the tables above, the Company recorded restructuring related charges of $2.0 million and $4.1 million for the three and six months ended July 2, 2017 , respectively, and $1.8 million and $2.4 million for the three and six months ended June 26, 2016 , respectively, related to the 2016 footprint realignment plan. The majority of charges in both periods constituted accelerated depreciation and other costs, principally as a result of the transfer of manufacturing operations to the new locations. As of July 2, 2017 , the Company has incurred net aggregate restructuring charges related to the 2016 footprint realignment plan of $13.4 million . Additionally, as of July 2, 2017 , the Company has incurred net aggregate accelerated depreciation and certain other costs, principally as a result of the transfer of manufacturing operations to new locations, of $10.5 million . These costs primarily were included in cost of goods sold. As of July 2, 2017 , the Company has a restructuring reserve of $8.7 million related to this plan, the majority of which relates to termination benefits. 2014 Footprint Realignment Plan In 2014, the Company initiated a restructuring plan (“the 2014 footprint realignment plan”) involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the second quarter 2014 and are expected to be substantially completed by the end of the first half of 2020.The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2014 footprint realignment plan of approximately $43 million to $48 million , of which an estimated $33 million to $38 million are expected to result in future cash outlays. The Company expects to incur $24 million to $30 million in aggregate capital expenditures under the plan . In addition to the restructuring charges set forth in the tables above, the Company recorded restructuring related charges of $0.5 million and $2.1 million for the three and six months ended July 2, 2017 , respectively, and $2.3 million and $4.4 million for the three and six months ended June 26, 2016 , respectively, related to the 2014 footprint realignment plan. The majority of charges in both periods constituted accelerated depreciation and other costs principally resulting from the transfer of manufacturing operations to new locations. As of July 2, 2017 , the Company has incurred net aggregate restructuring charges related to the 2014 footprint realignment plan of $11.3 million . Additionally, as of July 2, 2017 , the Company has incurred net aggregate accelerated depreciation and certain other costs of $25.0 million , principally resulting from the transfer of manufacturing operations from the existing locations to the new locations in connection with the plan. These costs primarily were included in cost of goods sold. As of July 2, 2017 , the Company has a restructuring reserve of $4.5 million in connection with the plan, all of which relates to termination benefits. For additional information regarding the Company's restructuring programs, see Note 4 to the Company's consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2016. Restructuring charges by reportable operating segment for the three and six months ended July 2, 2017 and June 26, 2016 are set forth in the following table: Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Dollars in thousands) (Dollars in thousands) Restructuring charges Vascular North America $ 361 $ 351 $ 1,109 $ 4,514 Anesthesia North America 564 364 811 2,239 Surgical North America — — — (20 ) EMEA (365 ) (949 ) 7,135 2,923 Asia — (2 ) — — OEM — (1 ) — 4 All other 310 118 4,760 189 Total restructuring charges $ 870 $ (119 ) $ 13,815 $ 9,849

Inventories, net

Inventories, net	6 Months Ended
	Jul. 02, 2017
Inventory Disclosure [Abstract]
Inventories, net	Note 5 — Inventories, net Inventories as of July 2, 2017 and December 31, 2016 consisted of the following: July 2, 2017 December 31, 2016 (Dollars in thousands) Raw materials $ 94,924 $ 65,319 Work-in-process 61,561 54,555 Finished goods 212,041 196,297 Inventories, net $ 368,526 $ 316,171

Goodwill and other intangible a

Goodwill and other intangible assets, net	6 Months Ended
	Jul. 02, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets, net	Note 6 — Goodwill and other intangible assets, net The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the six months ended July 2, 2017 : Vascular Anesthesia Surgical EMEA Asia OEM All Total (Dollars in thousands) Balance as of December 31, 2016 $ 345,546 $ 141,253 $ 250,912 $ 290,041 $ 138,185 $ 4,883 $ 105,900 $ 1,276,720 Goodwill related to acquisitions — 5,426 — 6,010 1,559 — 522,614 535,609 Currency translation and other adjustments (1,590 ) 215 — 24,729 6,217 — 12,176 41,747 Balance as of July 2, 2017 $ 343,956 $ 146,894 $ 250,912 $ 320,780 $ 145,961 $ 4,883 $ 640,690 $ 1,854,076 The following table provides information as of July 2, 2017 and December 31, 2016 regarding the gross carrying amount of, and accumulated amortization relating to intangible assets: Gross Carrying Amount Accumulated Amortization July 2, 2017 December 31, 2016 July 2, 2017 December 31, 2016 (Dollars in thousands) Customer relationships $ 892,574 $ 622,428 $ (259,002 ) $ (239,055 ) In-process research and development 33,595 16,532 — — Intellectual property 774,980 519,962 (226,354 ) (203,390 ) Distribution rights 23,452 23,021 (16,208 ) (15,239 ) Trade names 405,283 379,724 (16,862 ) (13,974 ) Non-compete agreements 2,900 2,692 (1,454 ) (1,038 ) $ 2,132,784 $ 1,564,359 $ (519,880 ) $ (472,696 )

Borrowings

Borrowings	6 Months Ended
	Jul. 02, 2017
Debt Disclosure [Abstract]
Borrowings	Note 7 — Borrowings The Company's borrowings at July 2, 2017 and December 31, 2016 were as follows: July 2, 2017 December 31, 2016 (Dollars in thousands) Senior Credit Facility: Revolving credit facility, at a rate of 3.22% at July 2, 2017, due 2022 $ 547,000 $ 210,000 Term loan facility, at a rate of 3.22% at July 2, 2017, due 2022 721,000 — 3.875% Convertible Senior Subordinated Notes due 2017 44,303 136,076 4.875% Senior Notes due 2026 400,000 400,000 5.25% Senior Notes due 2024 250,000 250,000 Securitization program, at a rate of 1.97% at July 2, 2017 50,000 50,000 2,012,303 1,046,076 Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017 (126 ) (2,707 ) Less: Unamortized debt issuance costs (12,422 ) (10,046 ) 1,999,755 1,033,323 Current borrowings (112,039 ) (183,071 ) Long-term borrowings $ 1,887,716 $ 850,252 Amended and restated senior credit facility On January 20, 2017, the Company entered into the Credit Agreement, which provides for a five year revolving credit facility of $1.0 billion and a term loan facility of $750.0 million . The obligations under the Credit Agreement are guaranteed (subject to certain exceptions and limitations) by substantially all of the material domestic subsidiaries of the Company and are secured by a lien on substantially all of the assets owned by the Company and each guarantor. The maturity date of the revolving credit facility under the Credit Agreement is January 20, 2022 and the term loan facility will mature on February 17, 2022. At the Company’s option, loans under the Credit Agreement will bear interest at a rate equal to adjusted LIBOR plus an applicable margin ranging from 1.25% to 2.50% or at an alternate base rate, which is defined as the highest of (i) the publicly announced prime rate of JPMorgan Chase Bank, N.A., the administrative agent under the Credit Agreement, (ii) 0.5% above the federal funds rate and (iii) 1% above adjusted LIBOR for a one month interest period on such day, plus an applicable margin ranging from 0.25% to 1.50% , in each case subject to adjustment based on the Company’s consolidated total leverage ratio (generally, Consolidated Total Funded Indebtedness, as defined in the Credit Agreement, on the date of determination to Consolidated EBITDA, as defined in the Credit Agreement, for the four most recent fiscal quarters ending on or preceding the date of determination). Overdue loans will bear interest at the rate otherwise applicable to such loans plus 2.00% . The Company is required to maintain a maximum total consolidated leverage ratio of 4.50 to 1.00 and a maximum consolidated senior secured leverage ratio (generally, Consolidated Senior Secured Funded Indebtedness, as defined in the Credit Agreement, on the date of determination to Consolidated EBITDA for the four most recent quarters ending on or preceding the date of determination) of 3.50 to 1.00. The Company is further required to maintain a consolidated interest coverage ratio (generally, Consolidated EBITDA for the four most recent fiscal quarters ending on or preceding the date of determination to Consolidated Interest Expense, as defined in the Credit Agreement, paid in cash for such period) of not less than 3.50 to 1.00. The Company capitalized $12.0 million related to transaction fees, including underwriters’ discounts and commissions, incurred in connection with the Credit Agreement. In addition, because the Company's entry into the Credit Agreement was considered a partial extinguishment of the indebtedness under its previously outstanding credit agreement, the Company recognized a loss on extinguishment of debt of $0.4 million during the first quarter 2017. 3.875% Convertible Senior Subordinated Note s Exchange Transactions On January 5, 2017, pursuant to separate, privately negotiated agreements between the Company and certain holders (the "Holders") of its 3.875% Convertible Senior Subordinated Notes due 2017 (the "Convertible Notes"), the Company paid cash and common stock (the "Exchange Consideration") to the Holders in exchange for $91.7 million aggregate principal amount of the Convertible Notes (the "Exchange Transactions"). The Exchange Consideration paid to each of the Holders per $1,000 principal amount of Convertible Notes was equal to: (i) $1,000 in cash, (ii) a number of shares of the Company's common stock equal to the amount of the conversion value of the Convertible Notes in excess of the $1,000 principal amount (the "Conversion Shares"), calculated on the basis of the average daily volume weighted average price per share of Company common stock over a specified period (the "Average Daily VWAP"), (iii) an inducement payment in additional shares of common stock (the "Inducement Shares") calculated based on the Average Daily VWAP; and (iv) cash in an amount equal to accrued and unpaid interest to, but not including, the closing date. As a result of the Exchange Transactions, the Company paid the Holders aggregate cash consideration of approximately $93.2 million (which includes approximately $1.5 million in accrued but previously unpaid interest) and issued and delivered to the Holders approximately 0.93 million shares of Company common stock (including both Conversion Shares and Inducement Shares). The Company funded the $93.2 million cash payment constituting part of the Exchange Consideration through borrowings under its revolving credit facility. As a result of the Exchange Transactions, the Company recognized a loss on extinguishment of debt of $5.2 million during the first quarter 2017. In connection with its entry into the Exchange Transactions, the Company also entered into bond hedge unwind agreements (the "Hedge Unwind Agreements") and warrant unwind agreements (the "Warrant Unwind Agreements") with the dealer counterparties to the convertible note hedge transactions and warrant transactions that were effected at the time of the initial issuance of the Convertible Notes. Under the Hedge Unwind Agreements, the number of then-outstanding call options issued to the Company under the Convertible Note hedge transactions (the "Call Options") was reduced to reflect proportionately the reduction in the outstanding principal amount of the Convertible Notes following the Exchange Transactions. Under the Warrant Unwind Agreements, the number of warrants then held by the dealer counterparties also was reduced. On a net basis, after giving effect to the Hedge Unwind Agreements and Warrant Unwind Agreements, the Company received 0.12 million shares of Company common stock from the dealer counterparties. Settlement and Conversions Upon Maturity The Convertible Notes matured on August 1, 2017 (the "Maturity Date"). On the Maturity Date, the Company repaid the remaining $44.3 million in aggregate principal amount of the Convertible Notes outstanding, together with unpaid interest due and owing on the Convertible Notes (the “Cash Payment”). In connection with the maturity of the Convertible Notes, $44.2 million in aggregate principal amount of the Convertible Notes were tendered to the Company for conversion (the "Converted Notes"). On the Maturity Date, in addition to the Cash Payment, the Company delivered to the holders of the Converted Notes, in the aggregate, 0.5 million shares of Company common stock. In connection with the conversions described above, the Company exercised the outstanding Call Options, and the counterparties to the Convertible Note hedge transactions delivered to the Company 0.5 million shares of Company common stock. Fair Value of Long-Term Borrowings The following table provides information regarding the fair value of the Company’s debt as of July 2, 2017 and December 31, 2016 , categorized by the level of inputs within the fair value hierarchy used to measure fair value: July 2, 2017 December 31, 2016 (Dollars in thousands) Level 1 $ 149,676 $ 344,765 Level 2 1,983,816 929,362 Total $ 2,133,492 $ 1,274,127 To determine the fair value of the debt categorized as Level 2 in the table above, the Company uses a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality and risk profile. The Company’s implied credit rating is a factor in determining the market interest yield curve. See Note 10, “Fair value measurement,” to the Company’s consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2016 for further information regarding the fair value hierarchy.

Financial instruments

Financial instruments	6 Months Ended
	Jul. 02, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial instruments	Note 8 — Financial instruments Foreign Currency Forward Contracts The Company uses derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage exposure related to foreign currency transactions. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage near term foreign currency denominated monetary assets and liabilities. For the three and six months ended July 2, 2017 , the Company recognized a loss related to non-designated foreign currency forward contracts of $2.3 million and $3.1 million , respectively. For the three and six months ended June 26, 2016 , the Company recognized a loss related to non-designated foreign currency forward contracts of $1.3 million and $1.6 million , respectively. The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of July 2, 2017 and December 31, 2016 : July 2, 2017 December 31, 2016 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 2,590 $ 667 Non-designated foreign currency forward contracts 290 490 Prepaid expenses and other current assets $ 2,880 $ 1,157 Total asset derivatives $ 2,880 $ 1,157 Liability derivatives: Designated foreign currency forward contracts $ 323 $ 2,139 Non-designated foreign currency forward contracts 166 118 Other current liabilities $ 489 $ 2,257 Total liability derivatives $ 489 $ 2,257 The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of July 2, 2017 and December 31, 2016 was $73.6 million and $101.8 million , respectively. The total notional amount for all open non-designated foreign currency forward contracts as of July 2, 2017 and December 31, 2016 was $92.2 million and $73.4 million , respectively. All open foreign currency forward contracts as of July 2, 2017 have durations of twelve months or less. There was no ineffectiveness related to the Company’s cash flow hedges during the three and six months ended July 2, 2017 and June 26, 2016 . Concentration of Credit Risk Concentrations of credit risk with respect to trade accounts receivable are generally limited due to the Company’s large number of customers and their diversity across many geographic areas. A portion of the Company’s trade accounts receivable outside the United States, however, include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the creditworthiness of those countries and the financial stability of their economies. Certain of the Company’s customers, particularly in Greece, Italy, Spain and Portugal, have extended or delayed payments for products and services already provided, raising collectability concerns regarding the Company’s accounts receivable from these customers. As a result, the Company continues to closely monitor the allowance for doubtful accounts with respect to these customers. The following table provides information regarding the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term trade accounts receivable represented by these customers' trade accounts receivable at July 2, 2017 and December 31, 2016 : July 2, 2017 December 31, 2016 (Dollars in thousands) Allowance for doubtful accounts (1) $ 9,813 $ 8,630 Current and long-term trade accounts receivable in Greece, Italy, Spain and Portugal (2) $ 51,896 $ 51,098 Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal 17.5 % 19.3 % (1) The current portion of the allowance for doubtful accounts was $2.7 million and $2.0 million as of July 2, 2017 and December 31, 2016, respectively, and was recognized in accounts receivable, net. (2) The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at July 2, 2017 and December 31, 2016 was $3.0 million and $2.7 million , respectively In January 2017, the Company sold $16.1 million of receivables outstanding with respect to publicly funded hospitals in Italy for $16.0 million . For the six months ended July 2, 2017 and June 26, 2016 , net revenues from customers in Greece, Italy, Spain and Portugal were $64.5 million and $63.7 million , respectively.

Fair value measurement

Fair value measurement	6 Months Ended
	Jul. 02, 2017
Fair Value Disclosures [Abstract]
Fair value measurement	Note 9 — Fair value measurement For a description of the fair value hierarchy, see Note 10 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2016 . The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of July 2, 2017 and December 31, 2016 : Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 8,252 $ 8,252 $ — $ — Derivative assets 2,880 — 2,880 — Derivative liabilities 489 — 489 — Contingent consideration liabilities (1) 6,712 — — 6,712 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 7,660 $ 7,660 $ — $ — Derivative assets 1,157 — 1,157 — Derivative liabilities 2,257 — 2,257 — Contingent consideration liabilities (1) 7,102 — — 7,102 (1) As of July 2, 2017 and December 31, 2016, (a) $0.6 million of contingent consideration liabilities were recognized in the current portion of contingent consideration, and (b) $6.1 million and $6.5 million of contingent consideration liabilities, respectively, were recognized in other liabilities in the condensed consolidated balance sheet. There were no transfers of financial assets or liabilities reported at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the six months ended July 2, 2017 . The following table provides information regarding changes, during the six months ended July 2, 2017 , in Level 3 financial liabilities related to contingent consideration, which are described below in this Note 9 under "Valuation Techniques": Contingent consideration 2017 (Dollars in thousands) Balance - December 31, 2016 $ 7,102 Payment (153 ) Revaluations (237 ) Balance - July 2, 2017 $ 6,712 Valuation Techniques The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices. The Company’s financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts. The Company uses foreign currency forward contracts to manage foreign currency transaction exposure as well as exposure to foreign currency denominated monetary assets and liabilities. The Company measures the fair value of the foreign currency forward contracts by calculating the amount required to enter into offsetting contracts with similar remaining maturities as of the measurement date, based on quoted market prices, and taking into account the creditworthiness of the counterparties. The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions. The Company determines the fair value of the liabilities for contingent consideration based on discounted cash flow analysis. This fair value measurement is based on significant inputs unobservable in the market, primarily estimated sales royalties and the discount rate and, therefore, constitutes a Level 3 measurement within the fair value hierarchy.

Shareholders' equity

Shareholders' equity	6 Months Ended
	Jul. 02, 2017
Equity [Abstract]
Shareholders' equity	Note 10 — Shareholders’ equity Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Shares in thousands) Basic 44,996 43,549 44,945 42,598 Dilutive effect of share-based awards 866 566 843 543 Dilutive effect of 3.875% Convertible Notes and warrants (1) 956 3,131 928 4,873 Diluted 46,818 47,246 46,716 48,014 (1) The reduction in the dilutive effect of the Convertible Notes and warrants during the three and six months ended July 2, 2017 as compared to three and six months ended June 26, 2016 is due principally to the Company’s repurchase of Convertible Notes and conversions by holders of the Convertible Notes during and subsequent to the three month period ended June 26, 2016. The weighted average number of shares that were antidilutive and therefore excluded from the calculation of earnings per share were 0.7 million and 0.6 million for the three and six months ended July 2, 2017 , respectively, and 5.0 million and 5.1 million for the three and six months ended June 26, 2016 , respectively. In connection with the issuance of the Convertible Notes, the Company entered into convertible note hedge and warrant agreements. The convertible note hedge, consisting of call options held by the Company, economically reduces the dilutive impact of the Convertible Notes. However, applicable accounting guidance requires the Company to separately address the dilutive impact of the warrants issued under the warrant agreements in computing diluted weighted average number of common shares outstanding, without giving effect to the anti-dilutive impact of the call options. The reduction in the weighted average number of diluted shares that would result from giving effect to the anti-dilutive impact of the call options would have been 0.5 million for the three and six months ended July 2, 2017 , and 1.7 million and 2.6 million for the three and six months ended June 26, 2016 , respectively. The treasury stock method is applied to the warrants because the average market price of the Company's common stock during the reporting periods presented exceeds the warrant exercise price of $74.65 per share, and assumes the proceeds from the exercise of the warrants are used by the Company to repurchase shares based on such average market price. Shares issuable upon exercise of the warrants that were included in the total diluted shares outstanding were 0.5 million and 0.4 million for the three and six months ended July 2, 2017 , respectively, and 1.5 million and 2.2 million for the three and six months ended June 26, 2016 , respectively. The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the six months ended July 2, 2017 and June 26, 2016 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2016 $ (2,424 ) $ (136,596 ) $ (299,697 ) $ (438,717 ) Other comprehensive income (loss) before reclassifications 2,684 (669 ) 112,667 114,682 Amounts reclassified from accumulated other comprehensive income 2,477 2,263 — 4,740 Net current-period other comprehensive income 5,161 1,594 112,667 119,422 Balance as of July 2, 2017 $ 2,737 $ (135,002 ) $ (187,030 ) $ (319,295 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance at December 31, 2015 $ (2,491 ) $ (138,887 ) $ (229,746 ) $ (371,124 ) Other comprehensive (loss) before reclassifications (1,684 ) 375 11,285 9,976 Amounts reclassified from accumulated other comprehensive loss 2,668 2,109 — 4,777 Net current-period other comprehensive income 984 2,484 11,285 14,753 Balance at June 26, 2016 $ (1,507 ) $ (136,403 ) $ (218,461 ) $ (356,371 ) The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and six months ended July 2, 2017 and June 26, 2016 : Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Dollars in thousands) Losses on foreign exchange contracts: Cost of goods sold $ 1,303 $ 1,501 $ 2,948 $ 3,372 Total before tax 1,303 1,501 2,948 3,372 Tax benefit (204 ) (363 ) (471 ) (704 ) Net of tax $ 1,099 $ 1,138 $ 2,477 $ 2,668 Amortization of pension and other postretirement benefit items: Actuarial losses (1) $ 1,727 $ 1,620 $ 3,453 $ 3,242 Prior-service costs (1) 30 14 59 28 Total before tax 1,757 1,634 3,512 3,270 Tax benefit (625 ) (581 ) (1,249 ) (1,161 ) Net of tax $ 1,132 $ 1,053 $ 2,263 $ 2,109 Total reclassifications, net of tax $ 2,231 $ 2,191 $ 4,740 $ 4,777 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans (see Note 12 for additional information). Mezzanine Equity As of December 31, 2016, the Company reclassified $1.8 million from additional paid-in capital to convertible notes in the mezzanine equity section of the Company's consolidated balance sheet. The reclassified amount represents the aggregate difference between the principal amount and the carrying value of the Convertible Notes purchased by the Company pursuant to the Exchange Transactions (see "3.875% Convertible Senior Subordinated Notes - Exchange Transactions" within Note 7) under agreements that were entered into prior to December 31,2016, but not consummated until January 5, 2017 . No reclassification was required as of July 2, 2017 .

Taxes on income from continuing

Taxes on income from continuing operations	6 Months Ended
	Jul. 02, 2017
Income Tax Disclosure [Abstract]
Taxes on income from continuing operations	Note 11 — Taxes on income from continuing operations Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 Effective income tax rate 13.4% 11.9% 7.4% 8.8% The effective income tax rate for the three and six months ended July 2, 2017 was 13.4% and 7.4% , respectively, and 11.9% and 8.8% for the three and six months ended June 26, 2016 , respectively. The effective income tax rate for the three and six months ended July 2, 2017 , as compared to the prior year periods, reflects an excess tax benefit associated with share based payments, recognized under the new FASB guidance adopted as of January 1, 2017. In addition, the effective tax rate for the six months ended July 2, 2017 reflects a tax benefit associated with costs incurred in connection with the Vascular Solutions acquisition. The effective tax rate for the three months ended June 26, 2016 reflects a tax benefit associated with the loss on extinguishment of debt. The effective tax rate for the six months ended June 26, 2016 reflects a tax benefit on the settlement of a foreign tax audit as well as the above mentioned benefit associated with the loss on extinguishment of debt.

Pension and other postretiremen

Pension and other postretirement benefits	6 Months Ended
	Jul. 02, 2017
Compensation and Retirement Disclosure [Abstract]
Pension and other postretirement benefits	Note 12 — Pension and other postretirement benefits The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. As of July 2, 2017 , no further benefits are being accrued under the Company’s U.S. defined benefit pension plans and the Company’s other postretirement benefit plans, other than certain postretirement benefit plans covering employees subject to a collective bargaining agreement. Net pension and other postretirement benefits expense (income) consist of the following: Pension Other Postretirement Benefits Pension Other Postretirement Benefits July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Dollars in thousands) Service cost $ 720 $ 655 $ 75 $ 111 $ 1,437 $ 1,307 $ 149 $ 222 Interest cost 3,789 3,929 379 407 7,574 7,849 757 813 Expected return on plan assets (6,750 ) (6,199 ) — — (13,493 ) (12,397 ) — — Net amortization and deferral 1,691 1,577 66 57 3,381 3,156 131 114 Net benefits expense (income) $ (550 ) $ (38 ) $ 520 $ 575 $ (1,101 ) $ (85 ) $ 1,037 $ 1,149

Commitments and contingent liab

Commitments and contingent liabilities	6 Months Ended
	Jul. 02, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingent liabilities	Note 13 — Commitments and contingent liabilities Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At July 2, 2017 , the Company has recorded $1.1 million and $5.5 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of July 2, 2017 . The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 15 - 20 years. Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment, environmental and other matters. As of July 2, 2017 , the Company has recorded accrued liabilities of $2.5 million in connection with such contingencies, representing its best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. Of the amount accrued as of July 2, 2017 , $1.7 million pertains to discontinued operations. During the first quarter 2017, Teleflex Medical Trading (Shanghai) Company, Ltd. (“Teleflex Shanghai”), one of the Company’s subsidiaries, eliminated a key distributor within its sales channel in China and undertook a distributor to direct sales conversion within that channel. On March 24, 2017, the distributor submitted an application with the Shanghai International Economy and Trade Arbitration Commission (“SHIAC”) for arbitration alleging, among other things, that Teleflex Shanghai wrongfully terminated its relationship with the distributor. Pursuant to a supplementary submission filed by the distributor with SHIAC in July 2017, the distributor is seeking to recover RMB 51.2 million ( $7.5 million ) in damages, and is also seeking to compel Teleflex Shanghai to repurchase Teleflex products that the distributor claims it purchased from Teleflex Shanghai at a total price of RMB 97.5 million ( $14.4 million ). Teleflex Shanghai intends to vigorously contest the distributor’s arbitration claim, and has filed a counterclaim seeking payment from the distributor of RMB 61.2 million ( $9.0 million ) in respect of outstanding trade receivables owed by the distributor to Teleflex Shanghai. At this time, the Company is unable to make an estimate of the amount of loss, if any, or range of possible loss that the Company could incur as a result of this matter. In 2006, the Company was named as a defendant in a wrongful death product liability lawsuit filed in the Louisiana State District Court for the Parish of Calcasieu, involving a product manufactured by the Company’s former marine business. In September 2014, the case was tried before a jury, which returned a verdict in favor of the Company. The plaintiff subsequently filed a motion for a new trial, which was granted, and the case was re-tried before a jury in December 2014. On December 5, 2014, the jury returned a verdict in favor of the plaintiff, awarding $0.1 million in compensatory damages and $23.0 million in punitive damages, plus pre- and post-judgment interest on the compensatory damages and post-judgment interest on the punitive damages. The Company filed an appeal with the Louisiana Court of Appeal, and the plaintiff filed a cross-appeal, seeking to overturn the trial court’s denial of pre-judgment interest on the punitive damages award. On June 29, 2016, the Louisiana Court of Appeal affirmed the trial court verdict in all respects. The Company and the plaintiff filed applications for a writ of certiorari (a request for review) to the Louisiana Supreme Court. On January 13, 2017, the Louisiana Supreme Court granted the Company's writ application. Following the submission of written briefs, oral arguments were held on May 1, 2017 and the parties currently are awaiting the court’s decision. As of July 2, 2017 , the Company has accrued a liability representing its best estimate of probable loss associated with this matter, which is included in the Company’s accrued liabilities for litigation matters relating to discontinued operations discussed in the preceding paragraph. The Company believes that any liability arising from this matter that is not covered by the Company's product liability insurance will not exceed $10.0 million . Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred. Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various tax authorities. As of July 2, 2017 , the most significant tax examinations in process are in Canada and Germany. The Company may establish reserves with respect to its uncertain tax positions, after which it adjusts its reserves to address developments with respect to these uncertain tax positions. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results. Other: The Company has various purchase commitments for materials, supplies and other items occurring in the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market prices.

Segment information

Segment information	6 Months Ended
	Jul. 02, 2017
Segment Reporting [Abstract]
Segment information	Note 14 — Segment information The following tables present the Company’s segment results for the three and six months ended July 2, 2017 and June 26, 2016 : Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Dollars in thousands) (Dollars in thousands) Revenue Vascular North America $ 93,522 $ 88,111 $ 187,371 $ 169,699 Anesthesia North America 49,081 49,194 97,288 95,151 Surgical North America 44,716 43,136 90,660 82,077 EMEA 131,962 131,705 262,695 253,800 Asia 63,988 63,191 112,941 112,347 OEM 45,132 40,298 88,478 74,275 All other 100,212 57,918 177,061 111,097 Consolidated net revenues $ 528,613 $ 473,553 $ 1,016,494 $ 898,446 Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Dollars in thousands) (Dollars in thousands) Operating profit Vascular North America $ 25,258 $ 21,994 $ 50,074 $ 41,650 Anesthesia North America 20,516 15,050 34,043 27,227 Surgical North America 17,287 12,348 33,667 25,604 EMEA 23,250 23,944 45,490 44,987 Asia 18,604 21,751 29,402 34,759 OEM 10,337 9,215 19,458 14,404 All other 11,267 7,436 4,966 13,179 Total segment operating profit (1) 126,519 111,738 217,100 201,810 Unallocated expenses (2) (16,317 ) (13,297 ) (46,079 ) (35,872 ) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 110,202 $ 98,441 $ 171,021 $ 165,938 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.

Condensed consolidating guarant

Condensed consolidating guarantor financial information	6 Months Ended
	Jul. 02, 2017
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed consolidating guarantor financial information	Note 15 — Condensed consolidating guarantor financial information Teleflex Incorporated (the "Parent Company") is the issuer of its 5.25% Senior Notes due 2024 (the "2024 Notes") and 4.875% Senior Notes due 2026 (the "2026 Notes"). Payment of the Parent Company's obligations under the 2024 Notes and 2026 Notes is guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income for the three and six months ended July 2, 2017 and June 26, 2016 , condensed consolidating balance sheets as of July 2, 2017 and December 31, 2016 and condensed consolidating statements of cash flows for the six months ended July 2, 2017 and June 26, 2016 , provide consolidated information for: a. Parent Company, the issuer of the guaranteed obligations; b. Guarantor Subsidiaries, on a combined basis; c. Non-Guarantor Subsidiaries (i.e., those subsidiaries of the Parent Company that have not guaranteed payment of the 2024 Notes and 2026 Notes), on a combined basis; and d. Parent Company and its subsidiaries on a consolidated basis. The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidating financial information, except for the use of the equity method of accounting to reflect ownership interests in subsidiaries, which are eliminated upon consolidation. Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries. TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Three Months Ended July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 338,620 $ 296,977 $ (106,984 ) $ 528,613 Cost of goods sold — 190,202 152,440 (104,313 ) 238,329 Gross profit — 148,418 144,537 (2,671 ) 290,284 Selling, general and administrative expenses 7,468 95,171 56,334 (39 ) 158,934 Research and development expenses 264 13,594 6,420 — 20,278 Restructuring charges — 1,335 (465 ) — 870 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (7,732 ) 38,318 82,248 (2,632 ) 110,202 Interest, net 51,073 (32,421 ) 1,081 — 19,733 Loss on extinguishment of debt 11 — — — 11 (Loss) income from continuing operations before taxes (58,816 ) 70,739 81,167 (2,632 ) 90,458 (Benefit) taxes on (loss) income from continuing operations (23,115 ) 22,123 14,210 (1,123 ) 12,095 Equity in net income of consolidated subsidiaries 114,064 58,861 240 (173,165 ) — Income from continuing operations 78,363 107,477 67,197 (174,674 ) 78,363 Operating loss from discontinued operations (566 ) — — — (566 ) Benefit on loss from discontinued operations (206 ) — — — (206 ) Loss from discontinued operations (360 ) — — — (360 ) Net income 78,003 107,477 67,197 (174,674 ) 78,003 Other comprehensive income 69,822 68,127 69,374 (137,501 ) 69,822 Comprehensive income $ 147,825 $ 175,604 $ 136,571 $ (312,175 ) $ 147,825 Three Months Ended June 26, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 280,430 $ 290,784 $ (97,661 ) $ 473,553 Cost of goods sold — 170,700 146,997 (100,543 ) 217,154 Gross profit — 109,730 143,787 2,882 256,399 Selling, general and administrative expenses 10,285 86,385 46,297 16 142,983 Research and development expenses 140 8,644 6,688 — 15,472 Restructuring charges — 557 (676 ) — (119 ) Gain on sale of assets — (378 ) — — (378 ) (Loss) income from continuing operations before interest, extinguishment of debt and taxes (10,425 ) 14,522 91,478 2,866 98,441 Interest, net 33,146 (22,437 ) 1,069 — 11,778 Loss on extinguishment of debt 19,261 — — — 19,261 (Loss) income from continuing operations before taxes (62,832 ) 36,959 90,409 2,866 67,402 (Benefit) taxes on (loss) income from continuing operations (23,077 ) 14,504 15,909 671 8,007 Equity in net income of consolidated subsidiaries 99,295 63,605 175 (163,075 ) — Income from continuing operations 59,540 86,060 74,675 (160,880 ) 59,395 Operating (loss) income from discontinued operations (373 ) — 379 — 6 Benefit on (loss) income from discontinued operations (136 ) — (51 ) — (187 ) (Loss) income from discontinued operations (237 ) — 430 — 193 Net income 59,303 86,060 75,105 (160,880 ) 59,588 Less: Income from continuing operations attributable to noncontrolling interest — — 285 — 285 Net income attributable to common shareholders 59,303 86,060 74,820 (160,880 ) 59,303 Other comprehensive loss attributable to common shareholders (8,441 ) (9,685 ) (11,378 ) 21,063 (8,441 ) Comprehensive income attributable to common shareholders $ 50,862 $ 76,375 $ 63,442 $ (139,817 ) $ 50,862 Six Months Ended July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 654,263 $ 573,292 $ (211,061 ) $ 1,016,494 Cost of goods sold — 382,203 296,336 (207,889 ) 470,650 Gross profit — 272,060 276,956 (3,172 ) 545,844 Selling, general and administrative expenses 27,987 189,214 105,178 524 322,903 Research and development expenses 499 24,780 12,826 — 38,105 Restructuring charges — 6,709 7,106 — 13,815 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (28,486 ) 51,357 151,846 (3,696 ) 171,021 Interest, net 98,747 (63,384 ) 1,927 — 37,290 Loss on extinguishment of debt 5,593 — — — 5,593 (Loss) income from continuing operations before taxes (132,826 ) 114,741 149,919 (3,696 ) 128,138 (Benefit) taxes on (loss) income from continuing operations (53,022 ) 36,608 26,439 (599 ) 9,426 Equity in net income of consolidated subsidiaries 198,516 114,663 456 (313,635 ) — Income from continuing operations 118,712 192,796 123,936 (316,732 ) 118,712 Operating loss from discontinued operations (848 ) — — — (848 ) Benefit on loss from discontinued operations (309 ) — — — (309 ) Loss from discontinued operations (539 ) — — — (539 ) Net income 118,173 192,796 123,936 (316,732 ) 118,173 Other comprehensive income 119,422 117,531 123,275 (240,806 ) 119,422 Comprehensive income $ 237,595 $ 310,327 $ 247,211 $ (557,538 ) $ 237,595 Six Months Ended June 26, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 539,341 $ 552,132 $ (193,027 ) $ 898,446 Cost of goods sold — 326,241 279,960 (189,301 ) 416,900 Gross profit — 213,100 272,172 (3,726 ) 481,546 Selling, general and administrative expenses 19,614 167,862 91,356 499 279,331 Research and development expenses 140 15,079 12,606 — 27,825 Restructuring charges — 5,315 4,534 — 9,849 Gain on sale of assets — (378 ) (1,019 ) — (1,397 ) (Loss) income from continuing operations before interest, extinguishment of debt and taxes (19,754 ) 25,222 164,695 (4,225 ) 165,938 Interest, net 66,190 (42,755 ) 2,047 — 25,482 Loss on extinguishment of debt 19,261 — — — 19,261 (Loss) income from continuing operations before taxes (105,205 ) 67,977 162,648 (4,225 ) 121,195 (Benefit) taxes on (loss) income from continuing operations (38,925 ) 26,181 23,773 (409 ) 10,620 Equity in net income of consolidated subsidiaries 176,752 121,505 343 (298,600 ) — Income from continuing operations 110,472 163,301 139,218 (302,416 ) 110,575 Operating (loss) income from discontinued operations (755 ) — 379 — (376 ) (Benefit) taxes on (loss) income from discontinued operations (275 ) — 18 — (257 ) (Loss) income from discontinued operations (480 ) — 361 — (119 ) Net income 109,992 163,301 139,579 (302,416 ) 110,456 Less: Income from continuing operations attributable to noncontrolling interest — — 464 — 464 Net income attributable to common shareholders 109,992 163,301 139,115 (302,416 ) 109,992 Other comprehensive income attributable to common shareholders 14,753 8,888 11,034 (19,922 ) 14,753 Comprehensive income attributable to common shareholders $ 124,745 $ 172,189 $ 150,149 $ (322,338 ) $ 124,745 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 56,699 $ 10,963 $ 608,552 $ — $ 676,214 Accounts receivable, net 2,236 34,592 262,539 4,335 303,702 Accounts receivable from consolidated subsidiaries 8,333 2,265,552 345,901 (2,619,786 ) — Inventories, net — 228,022 168,954 (28,450 ) 368,526 Prepaid expenses and other current assets 14,163 9,280 20,518 3,337 47,298 Prepaid taxes 4,490 — 7,760 (372 ) 11,878 Total current assets 85,921 2,548,409 1,414,224 (2,640,936 ) 1,407,618 Property, plant and equipment, net 2,398 212,907 153,996 — 369,301 Goodwill — 1,238,551 615,525 — 1,854,076 Intangibles assets, net — 1,152,095 460,809 — 1,612,904 Deferred tax assets 72,037 — 5,435 (75,509 ) 1,963 Notes receivable and other amounts due from consolidated subsidiaries 1,310,464 2,163,757 — (3,474,221 ) — Other assets 7,386,675 1,706,244 31,051 (9,079,808 ) 44,162 Total assets $ 8,857,495 $ 9,021,963 $ 2,681,040 $ (15,270,474 ) $ 5,290,024 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 62,039 $ — $ 50,000 $ — $ 112,039 Accounts payable 3,136 38,529 40,308 — 81,973 Accounts payable to consolidated subsidiaries 2,306,666 261,263 51,857 (2,619,786 ) — Accrued expenses 19,284 26,593 39,173 — 85,050 Current portion of contingent consideration — 584 — — 584 Payroll and benefit-related liabilities 17,855 26,071 35,025 — 78,951 Accrued interest 5,264 — 30 — 5,294 Income taxes payable — — 4,408 (970 ) 3,438 Other current liabilities 500 4,250 3,972 — 8,722 Total current liabilities 2,414,744 357,290 224,773 (2,620,756 ) 376,051 Long-term borrowings 1,887,716 — — — 1,887,716 Deferred tax liabilities — 508,629 34,914 (75,509 ) 468,034 Pension and postretirement benefit liabilities 80,154 31,026 17,155 — 128,335 Noncurrent liability for uncertain tax positions 1,729 13,781 2,868 — 18,378 Notes payable and other amounts due to consolidated subsidiaries 2,089,600 1,185,791 198,830 (3,474,221 ) — Other liabilities 25,023 13,961 13,997 — 52,981 Total liabilities 6,498,966 2,110,478 492,537 (6,170,486 ) 2,931,495 Total shareholders' equity 2,358,529 6,911,485 2,188,503 (9,099,988 ) 2,358,529 Total liabilities and shareholders' equity $ 8,857,495 $ 9,021,963 $ 2,681,040 $ (15,270,474 ) $ 5,290,024 December 31, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 14,571 $ 1,031 $ 528,187 $ — $ 543,789 Accounts receivable, net 2,551 8,768 255,815 4,859 271,993 Accounts receivable from consolidated subsidiaries 4,861 2,176,059 309,149 (2,490,069 ) — Inventories, net — 200,852 140,406 (25,087 ) 316,171 Prepaid expenses and other current assets 14,239 5,332 17,474 3,337 40,382 Prepaid taxes — — 7,766 413 8,179 Assets held for sale — — 2,879 — 2,879 Total current assets 36,222 2,392,042 1,261,676 (2,506,547 ) 1,183,393 Property, plant and equipment, net 2,566 163,847 136,486 — 302,899 Goodwill — 708,546 568,174 — 1,276,720 Intangibles assets, net — 640,999 450,664 — 1,091,663 Deferred tax assets 73,051 — 5,185 (76,524 ) 1,712 Notes receivable and other amounts due from consolidated subsidiaries 1,387,615 2,085,538 — (3,473,153 ) — Other assets 6,044,337 1,525,285 29,962 (7,564,758 ) 34,826 Total assets $ 7,543,791 $ 7,516,257 $ 2,452,147 $ (13,620,982 ) $ 3,891,213 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 133,071 $ — $ 50,000 $ — $ 183,071 Accounts payable 4,540 30,924 33,936 — 69,400 Accounts payable to consolidated subsidiaries 2,242,814 214,203 33,052 (2,490,069 ) — Accrued expenses 16,827 18,126 30,196 — 65,149 Current portion of contingent consideration — 587 — — 587 Payroll and benefit-related liabilities 20,610 26,672 35,397 — 82,679 Accrued interest 10,429 — 21 — 10,450 Income taxes payable 1,246 — 6,577 85 7,908 Other current liabilities 2,262 3,643 2,497 — 8,402 Total current liabilities 2,431,799 294,155 191,676 (2,489,984 ) 427,646 Long-term borrowings 850,252 — — — 850,252 Deferred tax liabilities — 316,526 31,375 (76,524 ) 271,377 Pension and postretirement benefit liabilities 85,645 31,561 15,856 — 133,062 Noncurrent liability for uncertain tax positions 1,169 13,684 2,667 — 17,520 Notes payable and other amounts due to consolidated subsidiaries 2,011,737 1,264,004 197,412 (3,473,153 ) — Other liabilities 23,848 15,695 12,472 — 52,015 Total liabilities 5,404,450 1,935,625 451,458 (6,039,661 ) 1,751,872 Convertible notes - redeemable equity component 1,824 — — — 1,824 Mezzanine equity 1,824 — — — 1,824 Total shareholders' equity 2,137,517 5,580,632 2,000,689 (7,581,321 ) 2,137,517 Total liabilities and shareholders' equity $ 7,543,791 $ 7,516,257 $ 2,452,147 $ (13,620,982 ) $ 3,891,213 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Six Months Ended July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (121,726 ) $ 232,874 $ 148,460 $ (61,918 ) $ 197,690 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (173 ) (19,760 ) (16,900 ) — (36,833 ) Proceeds from sale of assets — — 6,332 — 6,332 Payments for businesses and intangibles acquired, net of cash acquired (975,524 ) — (17,935 ) — (993,459 ) Net cash used in investing activities from continuing operations (975,697 ) (19,760 ) (28,503 ) — (1,023,960 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 1,194,500 — — — 1,194,500 Reduction in borrowings (228,273 ) — — — (228,273 ) Debt extinguishment, issuance and amendment fees (19,114 ) — — — (19,114 ) Net proceeds from share based compensation plans and the related tax impacts 1,305 — — — 1,305 Payments for contingent consideration — (153 ) — — (153 ) Dividends paid (30,590 ) — — — (30,590 ) Intercompany transactions 222,684 (203,029 ) (19,655 ) — — Intercompany dividends paid — — (61,918 ) 61,918 — Net cash provided by (used in) financing activities from continuing operations 1,140,512 (203,182 ) (81,573 ) 61,918 917,675 Cash flows from discontinued operations: Net cash used in operating activities (961 ) — — — (961 ) Net cash used in discontinued operations (961 ) — — — (961 ) Effect of exchange rate changes on cash and cash equivalents — — 41,981 — 41,981 Net increase in cash and cash equivalents 42,128 9,932 80,365 132,425 Cash and cash equivalents at the beginning of the period 14,571 1,031 528,187 — 543,789 Cash and cash equivalents at the end of the period $ 56,699 $ 10,963 $ 608,552 $ — $ 676,214 Six Months Ended June 26, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (29,648 ) $ 69,875 $ 141,261 $ — $ 181,488 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (146 ) (9,947 ) (9,442 ) — (19,535 ) Proceeds from sale of assets — 20,642 1,251 (17,908 ) 3,985 Payments for businesses and intangibles acquired, net of cash acquired — — (21,025 ) 17,908 (3,117 ) Net cash (used in) provided by investing activities from continuing operations (146 ) 10,695 (29,216 ) — (18,667 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 665,000 — — — 665,000 Reduction in borrowings (656,479 ) — — — (656,479 ) Debt extinguishment, issuance and amendment fees (8,182 ) — — — (8,182 ) Net proceeds from share based compensation plans and the related tax impacts 6,593 — — — 6,593 Payments for contingent consideration — (133 ) — — (133 ) Dividends paid (28,998 ) — — — (28,998 ) Intercompany transactions 81,640 (79,348 ) (2,292 ) — — Net cash provided by (used in) financing activities from continuing operations 59,574 (79,481 ) (2,292 ) — (22,199 ) Cash flows from discontinued operations: Net cash used in operating activities (1,183 ) — — — (1,183 ) Net cash used in discontinued operations (1,183 ) — — — (1,183 ) Effect of exchange rate changes on cash and cash equivalents — — (1,315 ) — (1,315 ) Net increase in cash and cash equivalents 28,597 1,089 108,438 — 138,124 Cash and cash equivalents at the beginning of the period 21,612 — 316,754 — 338,366 Cash and cash equivalents at the end of the period $ 50,209 $ 1,089 $ 425,192 $ — $ 476,490

New accounting standards (Polic

New accounting standards (Policies)	6 Months Ended
	Jul. 02, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	New accounting standards In May 2014, the Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. This new guidance, collectively with related guidance provided by the FASB, is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance is effective for annual periods beginning after December 15, 2017 and interim periods within those years. The Company will adopt this standard in the first quarter 2018 and expects to use the modified retrospective method of adoption by recognizing the cumulative effect of adopting this guidance as an adjustment to the Company's opening balance of retained earnings. Although the Company's evaluation of this guidance is ongoing, the Company's preliminary assessment indicates that the adoption of this guidance will not have a material impact on the Company’s results of operations, cash flows and financial position. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements; the guidance provides certain practical expedients. The Company is currently evaluating this guidance to determine its impact on the Company’s results of operations, cash flows and financial position. In March 2016, the FASB issued new guidance designed to simplify several aspects of the accounting for share-based payment transactions, including, among other things, guidance related to accounting for income taxes, modification of the criteria for classification of awards as either equity awards or liability awards where an employer withholds shares from an employee's share-based award for tax withholding purposes, and classification on the statement of cash flows of cash payments to a tax authority by an employer that withholds shares from an employee's award for tax withholding purposes. The Company adopted this guidance as of January 1, 2017. The Company has applied the new guidance requiring recognition of excess tax deficiencies and tax benefits in the income statement, rather than in additional paid-in-capital, as previously required. The adoption of the new standard increased net income and cash flows from operating activities by $1.1 million and $4.5 million ( $0.02 and $0.09 diluted earnings per share) for the three and six months ended July 2, 2017 , respectively. The Company will continue to estimate forfeitures of share-based awards at the time of grant, rather than recognize actual forfeitures as they occur, as permitted under the new guidance. In August 2016, the FASB issued new guidance with regard to eight specific issues pertaining to the classification of certain cash receipts and cash payments within the statement of cash flows. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted. The new guidance should generally be adopted using a retrospective transition method for each period presented. Although the Company's evaluation of this guidance is ongoing, the Company's preliminary assessment indicates that the adoption of this guidance will not have a material impact on the Company's cash flows. In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The guidance is effective for annual periods beginning after December 15, 2017, and early adoption is permitted as of the beginning of an annual reporting period. The guidance should be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the annual period of adoption. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated financial position or results of operations. In January 2017, the FASB issued new guidance to clarify the definition of a “business,” with the objective of assisting entities in evaluating whether a transaction should be accounted for as an acquisition (or disposal) of assets or as an acquisition of a business. The definition of a business affects many areas of accounting, including acquisitions, disposals, goodwill and consolidation. The guidance generally defines a business as an integrated set of activities and assets (collectively referred to as a “set”) that is capable of being conducted and managed for the purpose of providing a return to investors or other owners, members, or participants. The guidance further provides that, to be considered a business, a set must meet specified requirements. However, the guidance also states that, if substantially all of the fair value of gross assets acquired (subject to specified exceptions) is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not considered a business and no further analysis is required. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted under specified circumstances. In January 2017, the FASB issued guidance to simplify the quantitative test for goodwill impairment. Under current guidance, if a reporting unit’s carrying value exceeds its fair value, the entity must determine the implied value of goodwill. This determination is made by deducting the fair value of a reporting unit’s identifiable assets and liabilities from the fair value of the reporting unit as a whole as if the reporting unit had just been acquired. Under the new guidance, a determination of the implied value of goodwill will no longer be required; a goodwill impairment will be equal to the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The revised guidance is effective for fiscal years, and any interim goodwill impairment tests within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated financial position or results of operations. In March 2017, the FASB issued new guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The new guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017 and generally is required to be applied retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated results of operations. In May 2017, the FASB issued new guidance to provide clarity and reduce diversity of practice as to when an entity should account for the effects of a modification of the terms and conditions of a share-based payment award. The new guidance generally provides that modification accounting is to be applied unless the fair value (or, if applicable, calculated or intrinsic value), vesting conditions and classification as an equity instrument or liability instrument of the award are the same as was the case prior to the modification. The new guidance does not change the guidance regarding the implementation of modification accounting, if required. The new guidance is effective for reporting periods beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated results of operations. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the Company’s results of operations, cash flows or financial position.

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jul. 02, 2017
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table presents the purchase price allocation among the assets acquired and liabilities assumed with respect to the Vascular Solutions acquisition: (Dollars in thousands) Assets Current assets $ 63,867 Property, plant and equipment 46,616 Intangible assets 539,250 Goodwill 522,614 Other assets 728 Total assets acquired 1,173,075 Less: Current liabilities 15,079 Deferred tax liabilities 182,472 Liabilities assumed 197,551 Net assets acquired $ 975,524
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination	The following table sets forth the components of identifiable intangible assets acquired and the ranges of the useful lives as of the date of the Vascular Solutions acquisition: Fair value Useful life range (Dollars in thousands) (Years) Intellectual property 248,200 10- 20 In-process research and development ("IPR&D") 15,600 Indefinite Trade names 16,650 20 Customer lists 258,800 25
Business Acquisition, Pro Forma Information	The following unaudited pro forma combined financial information for the three and six months ended July 2, 2017 and June 26, 2016 , respectively, gives effect to the Vascular Solutions acquisition as if it was completed at the beginning of the earliest period presented. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company. Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Dollars and shares in thousands, except per share) Net revenue $ 528,613 $ 514,574 $ 1,039,318 $ 978,697 Net income $ 79,221 $ 59,352 $ 128,302 $ 77,252 Basic earnings per common share: Net income $ 1.76 $ 1.36 $ 2.85 $ 1.81 Diluted earnings per common share: Net income $ 1.69 $ 1.26 $ 2.75 $ 1.61 Weighted average common shares outstanding: Basic 44,996 43,549 44,945 42,598 Diluted 46,818 47,246 46,716 48,014

Restructuring charges (Tables)

Restructuring charges (Tables)	6 Months Ended
	Jul. 02, 2017
Restructuring and Related Activities [Abstract]
Restructuring and Other Impairment Charges	The following tables provide information regarding restructuring charges recognized by the Company for the three and six months ended July 2, 2017 and June 26, 2016 : Three Months Ended July 2, 2017 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2017 Vascular Solutions integration program $ 370 $ — $ — $ 34 $ 404 2017 EMEA restructuring program (584 ) — — — (584 ) 2016 Footprint realignment plan 286 10 (4 ) 99 391 2014 Footprint realignment plan (121 ) 14 — (7 ) (114 ) Other restructuring programs (1) 661 11 79 22 773 Total restructuring charges $ 612 $ 35 $ 75 $ 148 $ 870 Three Months Ended June 26, 2016 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2016 Footprint realignment plan $ (279 ) $ — $ — $ 286 $ 7 2015 Restructuring programs (442 ) 55 115 25 (247 ) 2014 Footprint realignment plan 112 — — 9 121 Total restructuring charges $ (609 ) $ 55 $ 115 $ 320 $ (119 ) Six Months Ended July 2, 2017 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2017 Vascular Solutions integration program $ 4,853 $ — $ — $ 34 $ 4,887 2017 EMEA restructuring program 6,536 — — — 6,536 2016 Footprint realignment plan 825 22 (75 ) 129 901 2014 Footprint realignment plan 182 14 — 1 197 Other restructuring programs (1) 965 58 209 62 1,294 Total restructuring charges $ 13,361 $ 94 $ 134 $ 226 $ 13,815 Six Months Ended June 26, 2016 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2016 Footprint realignment plan $ 10,068 $ — $ — $ 286 $ 10,354 2015 Restructuring programs (399 ) 178 93 118 (10 ) 2014 Footprint realignment plan (426 ) — — 11 (415 ) Other restructuring programs (2) — — (86 ) 6 (80 ) Total restructuring charges $ 9,243 $ 178 $ 7 421 $ 9,849 (1) Other restructuring programs include the 2017 Pyng Integration program, the 2016 Other Restructuring programs , the 2015 Restructuring programs, and the 2014 European Restructuring plan. The Company committed to the 2017 Pyng Integration program, which relates to the integration of Pyng into Teleflex, during the second quarter 2017. For a description of the 2015 Restructuring programs, see Note 4 to the Company’s consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2016. (2) Other restructuring programs includes the 2014 European Restructuring Plan, the Other 2014 restructuring programs, the 2013 Restructuring programs and the LMA restructuring program. For a description of these plans, see Note 4 to the Company’s consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2016. Restructuring charges by reportable operating segment for the three and six months ended July 2, 2017 and June 26, 2016 are set forth in the following table: Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Dollars in thousands) (Dollars in thousands) Restructuring charges Vascular North America $ 361 $ 351 $ 1,109 $ 4,514 Anesthesia North America 564 364 811 2,239 Surgical North America — — — (20 ) EMEA (365 ) (949 ) 7,135 2,923 Asia — (2 ) — — OEM — (1 ) — 4 All other 310 118 4,760 189 Total restructuring charges $ 870 $ (119 ) $ 13,815 $ 9,849

Inventories, net (Tables)

Inventories, net (Tables)	6 Months Ended
	Jul. 02, 2017
Inventory Disclosure [Abstract]
Inventories, net	Inventories as of July 2, 2017 and December 31, 2016 consisted of the following: July 2, 2017 December 31, 2016 (Dollars in thousands) Raw materials $ 94,924 $ 65,319 Work-in-process 61,561 54,555 Finished goods 212,041 196,297 Inventories, net $ 368,526 $ 316,171

Goodwill and other intangible28

Goodwill and other intangible assets, net (Tables)	6 Months Ended
	Jul. 02, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the six months ended July 2, 2017 : Vascular Anesthesia Surgical EMEA Asia OEM All Total (Dollars in thousands) Balance as of December 31, 2016 $ 345,546 $ 141,253 $ 250,912 $ 290,041 $ 138,185 $ 4,883 $ 105,900 $ 1,276,720 Goodwill related to acquisitions — 5,426 — 6,010 1,559 — 522,614 535,609 Currency translation and other adjustments (1,590 ) 215 — 24,729 6,217 — 12,176 41,747 Balance as of July 2, 2017 $ 343,956 $ 146,894 $ 250,912 $ 320,780 $ 145,961 $ 4,883 $ 640,690 $ 1,854,076
Schedule of Finite-Lived Intangible Assets	The following table provides information as of July 2, 2017 and December 31, 2016 regarding the gross carrying amount of, and accumulated amortization relating to intangible assets: Gross Carrying Amount Accumulated Amortization July 2, 2017 December 31, 2016 July 2, 2017 December 31, 2016 (Dollars in thousands) Customer relationships $ 892,574 $ 622,428 $ (259,002 ) $ (239,055 ) In-process research and development 33,595 16,532 — — Intellectual property 774,980 519,962 (226,354 ) (203,390 ) Distribution rights 23,452 23,021 (16,208 ) (15,239 ) Trade names 405,283 379,724 (16,862 ) (13,974 ) Non-compete agreements 2,900 2,692 (1,454 ) (1,038 ) $ 2,132,784 $ 1,564,359 $ (519,880 ) $ (472,696 )

Borrowings (Tables)

Borrowings (Tables)	6 Months Ended
	Jul. 02, 2017
Debt Disclosure [Abstract]
Components of Long-Term Debt	The Company's borrowings at July 2, 2017 and December 31, 2016 were as follows: July 2, 2017 December 31, 2016 (Dollars in thousands) Senior Credit Facility: Revolving credit facility, at a rate of 3.22% at July 2, 2017, due 2022 $ 547,000 $ 210,000 Term loan facility, at a rate of 3.22% at July 2, 2017, due 2022 721,000 — 3.875% Convertible Senior Subordinated Notes due 2017 44,303 136,076 4.875% Senior Notes due 2026 400,000 400,000 5.25% Senior Notes due 2024 250,000 250,000 Securitization program, at a rate of 1.97% at July 2, 2017 50,000 50,000 2,012,303 1,046,076 Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017 (126 ) (2,707 ) Less: Unamortized debt issuance costs (12,422 ) (10,046 ) 1,999,755 1,033,323 Current borrowings (112,039 ) (183,071 ) Long-term borrowings $ 1,887,716 $ 850,252
Fair Value of Long-Term Debt	The following table provides information regarding the fair value of the Company’s debt as of July 2, 2017 and December 31, 2016 , categorized by the level of inputs within the fair value hierarchy used to measure fair value: July 2, 2017 December 31, 2016 (Dollars in thousands) Level 1 $ 149,676 $ 344,765 Level 2 1,983,816 929,362 Total $ 2,133,492 $ 1,274,127

Financial instruments (Tables)

Financial instruments (Tables)	6 Months Ended
	Jul. 02, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Values of Derivative Instruments Designated as Hedging Instruments	The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of July 2, 2017 and December 31, 2016 : July 2, 2017 December 31, 2016 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 2,590 $ 667 Non-designated foreign currency forward contracts 290 490 Prepaid expenses and other current assets $ 2,880 $ 1,157 Total asset derivatives $ 2,880 $ 1,157 Liability derivatives: Designated foreign currency forward contracts $ 323 $ 2,139 Non-designated foreign currency forward contracts 166 118 Other current liabilities $ 489 $ 2,257 Total liability derivatives $ 489 $ 2,257
Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts	The following table provides information regarding the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term trade accounts receivable represented by these customers' trade accounts receivable at July 2, 2017 and December 31, 2016 : July 2, 2017 December 31, 2016 (Dollars in thousands) Allowance for doubtful accounts (1) $ 9,813 $ 8,630 Current and long-term trade accounts receivable in Greece, Italy, Spain and Portugal (2) $ 51,896 $ 51,098 Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal 17.5 % 19.3 % (1) The current portion of the allowance for doubtful accounts was $2.7 million and $2.0 million as of July 2, 2017 and December 31, 2016, respectively, and was recognized in accounts receivable, net. (2) The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at July 2, 2017 and December 31, 2016 was $3.0 million and $2.7 million , respectively In January 2017, the Company sold $16.1 million of receivables outstanding with respect to publicly funded hospitals in Italy for $16.0 million .

Fair value measurement (Tables)

Fair value measurement (Tables)	6 Months Ended
	Jul. 02, 2017
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of July 2, 2017 and December 31, 2016 : Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 8,252 $ 8,252 $ — $ — Derivative assets 2,880 — 2,880 — Derivative liabilities 489 — 489 — Contingent consideration liabilities (1) 6,712 — — 6,712 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 7,660 $ 7,660 $ — $ — Derivative assets 1,157 — 1,157 — Derivative liabilities 2,257 — 2,257 — Contingent consideration liabilities (1) 7,102 — — 7,102 (1) As of July 2, 2017 and December 31, 2016, (a) $0.6 million of contingent consideration liabilities were recognized in the current portion of contingent consideration, and (b) $6.1 million and $6.5 million of contingent consideration liabilities, respectively, were recognized in other liabilities in the condensed consolidated balance sheet.
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	The following table provides information regarding changes, during the six months ended July 2, 2017 , in Level 3 financial liabilities related to contingent consideration, which are described below in this Note 9 under "Valuation Techniques": Contingent consideration 2017 (Dollars in thousands) Balance - December 31, 2016 $ 7,102 Payment (153 ) Revaluations (237 ) Balance - July 2, 2017 $ 6,712

Shareholders' equity (Tables)

Shareholders' equity (Tables)	6 Months Ended
	Jul. 02, 2017
Equity [Abstract]
Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding	The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Shares in thousands) Basic 44,996 43,549 44,945 42,598 Dilutive effect of share-based awards 866 566 843 543 Dilutive effect of 3.875% Convertible Notes and warrants (1) 956 3,131 928 4,873 Diluted 46,818 47,246 46,716 48,014 (1) The reduction in the dilutive effect of the Convertible Notes and warrants during the three and six months ended July 2, 2017 as compared to three and six months ended June 26, 2016 is due principally to the Company’s repurchase of Convertible Notes and conversions by holders of the Convertible Notes during and subsequent to the three month period ended June 26, 2016.
Change in Accumulated Other Comprehensive Income (Loss)	The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the six months ended July 2, 2017 and June 26, 2016 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2016 $ (2,424 ) $ (136,596 ) $ (299,697 ) $ (438,717 ) Other comprehensive income (loss) before reclassifications 2,684 (669 ) 112,667 114,682 Amounts reclassified from accumulated other comprehensive income 2,477 2,263 — 4,740 Net current-period other comprehensive income 5,161 1,594 112,667 119,422 Balance as of July 2, 2017 $ 2,737 $ (135,002 ) $ (187,030 ) $ (319,295 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance at December 31, 2015 $ (2,491 ) $ (138,887 ) $ (229,746 ) $ (371,124 ) Other comprehensive (loss) before reclassifications (1,684 ) 375 11,285 9,976 Amounts reclassified from accumulated other comprehensive loss 2,668 2,109 — 4,777 Net current-period other comprehensive income 984 2,484 11,285 14,753 Balance at June 26, 2016 $ (1,507 ) $ (136,403 ) $ (218,461 ) $ (356,371 )
Reclassification of Gain/Losses into Income/Expense, Net of Tax	The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and six months ended July 2, 2017 and June 26, 2016 : Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Dollars in thousands) Losses on foreign exchange contracts: Cost of goods sold $ 1,303 $ 1,501 $ 2,948 $ 3,372 Total before tax 1,303 1,501 2,948 3,372 Tax benefit (204 ) (363 ) (471 ) (704 ) Net of tax $ 1,099 $ 1,138 $ 2,477 $ 2,668 Amortization of pension and other postretirement benefit items: Actuarial losses (1) $ 1,727 $ 1,620 $ 3,453 $ 3,242 Prior-service costs (1) 30 14 59 28 Total before tax 1,757 1,634 3,512 3,270 Tax benefit (625 ) (581 ) (1,249 ) (1,161 ) Net of tax $ 1,132 $ 1,053 $ 2,263 $ 2,109 Total reclassifications, net of tax $ 2,231 $ 2,191 $ 4,740 $ 4,777 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes on income from continui33

Taxes on income from continuing operations (Tables)	6 Months Ended
	Jul. 02, 2017
Income Tax Disclosure [Abstract]
Effective Income Tax Rate	Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 Effective income tax rate 13.4% 11.9% 7.4% 8.8%

Pension and other postretirem34

Pension and other postretirement benefits (Tables)	6 Months Ended
	Jul. 02, 2017
Compensation and Retirement Disclosure [Abstract]
Net Benefit Cost of Pension and Postretirement Benefit Plans	Net pension and other postretirement benefits expense (income) consist of the following: Pension Other Postretirement Benefits Pension Other Postretirement Benefits July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Dollars in thousands) Service cost $ 720 $ 655 $ 75 $ 111 $ 1,437 $ 1,307 $ 149 $ 222 Interest cost 3,789 3,929 379 407 7,574 7,849 757 813 Expected return on plan assets (6,750 ) (6,199 ) — — (13,493 ) (12,397 ) — — Net amortization and deferral 1,691 1,577 66 57 3,381 3,156 131 114 Net benefits expense (income) $ (550 ) $ (38 ) $ 520 $ 575 $ (1,101 ) $ (85 ) $ 1,037 $ 1,149

Segment information (Tables)

Segment information (Tables)	6 Months Ended
	Jul. 02, 2017
Segment Reporting [Abstract]
Segment Results	The following tables present the Company’s segment results for the three and six months ended July 2, 2017 and June 26, 2016 : Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Dollars in thousands) (Dollars in thousands) Revenue Vascular North America $ 93,522 $ 88,111 $ 187,371 $ 169,699 Anesthesia North America 49,081 49,194 97,288 95,151 Surgical North America 44,716 43,136 90,660 82,077 EMEA 131,962 131,705 262,695 253,800 Asia 63,988 63,191 112,941 112,347 OEM 45,132 40,298 88,478 74,275 All other 100,212 57,918 177,061 111,097 Consolidated net revenues $ 528,613 $ 473,553 $ 1,016,494 $ 898,446 Three Months Ended Six Months Ended July 2, 2017 June 26, 2016 July 2, 2017 June 26, 2016 (Dollars in thousands) (Dollars in thousands) Operating profit Vascular North America $ 25,258 $ 21,994 $ 50,074 $ 41,650 Anesthesia North America 20,516 15,050 34,043 27,227 Surgical North America 17,287 12,348 33,667 25,604 EMEA 23,250 23,944 45,490 44,987 Asia 18,604 21,751 29,402 34,759 OEM 10,337 9,215 19,458 14,404 All other 11,267 7,436 4,966 13,179 Total segment operating profit (1) 126,519 111,738 217,100 201,810 Unallocated expenses (2) (16,317 ) (13,297 ) (46,079 ) (35,872 ) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 110,202 $ 98,441 $ 171,021 $ 165,938 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.

Condensed consolidating guara36

Condensed consolidating guarantor financial information (Tables)	6 Months Ended
	Jul. 02, 2017
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Three Months Ended July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 338,620 $ 296,977 $ (106,984 ) $ 528,613 Cost of goods sold — 190,202 152,440 (104,313 ) 238,329 Gross profit — 148,418 144,537 (2,671 ) 290,284 Selling, general and administrative expenses 7,468 95,171 56,334 (39 ) 158,934 Research and development expenses 264 13,594 6,420 — 20,278 Restructuring charges — 1,335 (465 ) — 870 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (7,732 ) 38,318 82,248 (2,632 ) 110,202 Interest, net 51,073 (32,421 ) 1,081 — 19,733 Loss on extinguishment of debt 11 — — — 11 (Loss) income from continuing operations before taxes (58,816 ) 70,739 81,167 (2,632 ) 90,458 (Benefit) taxes on (loss) income from continuing operations (23,115 ) 22,123 14,210 (1,123 ) 12,095 Equity in net income of consolidated subsidiaries 114,064 58,861 240 (173,165 ) — Income from continuing operations 78,363 107,477 67,197 (174,674 ) 78,363 Operating loss from discontinued operations (566 ) — — — (566 ) Benefit on loss from discontinued operations (206 ) — — — (206 ) Loss from discontinued operations (360 ) — — — (360 ) Net income 78,003 107,477 67,197 (174,674 ) 78,003 Other comprehensive income 69,822 68,127 69,374 (137,501 ) 69,822 Comprehensive income $ 147,825 $ 175,604 $ 136,571 $ (312,175 ) $ 147,825 Three Months Ended June 26, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 280,430 $ 290,784 $ (97,661 ) $ 473,553 Cost of goods sold — 170,700 146,997 (100,543 ) 217,154 Gross profit — 109,730 143,787 2,882 256,399 Selling, general and administrative expenses 10,285 86,385 46,297 16 142,983 Research and development expenses 140 8,644 6,688 — 15,472 Restructuring charges — 557 (676 ) — (119 ) Gain on sale of assets — (378 ) — — (378 ) (Loss) income from continuing operations before interest, extinguishment of debt and taxes (10,425 ) 14,522 91,478 2,866 98,441 Interest, net 33,146 (22,437 ) 1,069 — 11,778 Loss on extinguishment of debt 19,261 — — — 19,261 (Loss) income from continuing operations before taxes (62,832 ) 36,959 90,409 2,866 67,402 (Benefit) taxes on (loss) income from continuing operations (23,077 ) 14,504 15,909 671 8,007 Equity in net income of consolidated subsidiaries 99,295 63,605 175 (163,075 ) — Income from continuing operations 59,540 86,060 74,675 (160,880 ) 59,395 Operating (loss) income from discontinued operations (373 ) — 379 — 6 Benefit on (loss) income from discontinued operations (136 ) — (51 ) — (187 ) (Loss) income from discontinued operations (237 ) — 430 — 193 Net income 59,303 86,060 75,105 (160,880 ) 59,588 Less: Income from continuing operations attributable to noncontrolling interest — — 285 — 285 Net income attributable to common shareholders 59,303 86,060 74,820 (160,880 ) 59,303 Other comprehensive loss attributable to common shareholders (8,441 ) (9,685 ) (11,378 ) 21,063 (8,441 ) Comprehensive income attributable to common shareholders $ 50,862 $ 76,375 $ 63,442 $ (139,817 ) $ 50,862 Six Months Ended July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 654,263 $ 573,292 $ (211,061 ) $ 1,016,494 Cost of goods sold — 382,203 296,336 (207,889 ) 470,650 Gross profit — 272,060 276,956 (3,172 ) 545,844 Selling, general and administrative expenses 27,987 189,214 105,178 524 322,903 Research and development expenses 499 24,780 12,826 — 38,105 Restructuring charges — 6,709 7,106 — 13,815 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (28,486 ) 51,357 151,846 (3,696 ) 171,021 Interest, net 98,747 (63,384 ) 1,927 — 37,290 Loss on extinguishment of debt 5,593 — — — 5,593 (Loss) income from continuing operations before taxes (132,826 ) 114,741 149,919 (3,696 ) 128,138 (Benefit) taxes on (loss) income from continuing operations (53,022 ) 36,608 26,439 (599 ) 9,426 Equity in net income of consolidated subsidiaries 198,516 114,663 456 (313,635 ) — Income from continuing operations 118,712 192,796 123,936 (316,732 ) 118,712 Operating loss from discontinued operations (848 ) — — — (848 ) Benefit on loss from discontinued operations (309 ) — — — (309 ) Loss from discontinued operations (539 ) — — — (539 ) Net income 118,173 192,796 123,936 (316,732 ) 118,173 Other comprehensive income 119,422 117,531 123,275 (240,806 ) 119,422 Comprehensive income $ 237,595 $ 310,327 $ 247,211 $ (557,538 ) $ 237,595 Six Months Ended June 26, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 539,341 $ 552,132 $ (193,027 ) $ 898,446 Cost of goods sold — 326,241 279,960 (189,301 ) 416,900 Gross profit — 213,100 272,172 (3,726 ) 481,546 Selling, general and administrative expenses 19,614 167,862 91,356 499 279,331 Research and development expenses 140 15,079 12,606 — 27,825 Restructuring charges — 5,315 4,534 — 9,849 Gain on sale of assets — (378 ) (1,019 ) — (1,397 ) (Loss) income from continuing operations before interest, extinguishment of debt and taxes (19,754 ) 25,222 164,695 (4,225 ) 165,938 Interest, net 66,190 (42,755 ) 2,047 — 25,482 Loss on extinguishment of debt 19,261 — — — 19,261 (Loss) income from continuing operations before taxes (105,205 ) 67,977 162,648 (4,225 ) 121,195 (Benefit) taxes on (loss) income from continuing operations (38,925 ) 26,181 23,773 (409 ) 10,620 Equity in net income of consolidated subsidiaries 176,752 121,505 343 (298,600 ) — Income from continuing operations 110,472 163,301 139,218 (302,416 ) 110,575 Operating (loss) income from discontinued operations (755 ) — 379 — (376 ) (Benefit) taxes on (loss) income from discontinued operations (275 ) — 18 — (257 ) (Loss) income from discontinued operations (480 ) — 361 — (119 ) Net income 109,992 163,301 139,579 (302,416 ) 110,456 Less: Income from continuing operations attributable to noncontrolling interest — — 464 — 464 Net income attributable to common shareholders 109,992 163,301 139,115 (302,416 ) 109,992 Other comprehensive income attributable to common shareholders 14,753 8,888 11,034 (19,922 ) 14,753 Comprehensive income attributable to common shareholders $ 124,745 $ 172,189 $ 150,149 $ (322,338 ) $ 124,745
Condensed Consolidating Balance Sheets	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 56,699 $ 10,963 $ 608,552 $ — $ 676,214 Accounts receivable, net 2,236 34,592 262,539 4,335 303,702 Accounts receivable from consolidated subsidiaries 8,333 2,265,552 345,901 (2,619,786 ) — Inventories, net — 228,022 168,954 (28,450 ) 368,526 Prepaid expenses and other current assets 14,163 9,280 20,518 3,337 47,298 Prepaid taxes 4,490 — 7,760 (372 ) 11,878 Total current assets 85,921 2,548,409 1,414,224 (2,640,936 ) 1,407,618 Property, plant and equipment, net 2,398 212,907 153,996 — 369,301 Goodwill — 1,238,551 615,525 — 1,854,076 Intangibles assets, net — 1,152,095 460,809 — 1,612,904 Deferred tax assets 72,037 — 5,435 (75,509 ) 1,963 Notes receivable and other amounts due from consolidated subsidiaries 1,310,464 2,163,757 — (3,474,221 ) — Other assets 7,386,675 1,706,244 31,051 (9,079,808 ) 44,162 Total assets $ 8,857,495 $ 9,021,963 $ 2,681,040 $ (15,270,474 ) $ 5,290,024 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 62,039 $ — $ 50,000 $ — $ 112,039 Accounts payable 3,136 38,529 40,308 — 81,973 Accounts payable to consolidated subsidiaries 2,306,666 261,263 51,857 (2,619,786 ) — Accrued expenses 19,284 26,593 39,173 — 85,050 Current portion of contingent consideration — 584 — — 584 Payroll and benefit-related liabilities 17,855 26,071 35,025 — 78,951 Accrued interest 5,264 — 30 — 5,294 Income taxes payable — — 4,408 (970 ) 3,438 Other current liabilities 500 4,250 3,972 — 8,722 Total current liabilities 2,414,744 357,290 224,773 (2,620,756 ) 376,051 Long-term borrowings 1,887,716 — — — 1,887,716 Deferred tax liabilities — 508,629 34,914 (75,509 ) 468,034 Pension and postretirement benefit liabilities 80,154 31,026 17,155 — 128,335 Noncurrent liability for uncertain tax positions 1,729 13,781 2,868 — 18,378 Notes payable and other amounts due to consolidated subsidiaries 2,089,600 1,185,791 198,830 (3,474,221 ) — Other liabilities 25,023 13,961 13,997 — 52,981 Total liabilities 6,498,966 2,110,478 492,537 (6,170,486 ) 2,931,495 Total shareholders' equity 2,358,529 6,911,485 2,188,503 (9,099,988 ) 2,358,529 Total liabilities and shareholders' equity $ 8,857,495 $ 9,021,963 $ 2,681,040 $ (15,270,474 ) $ 5,290,024 December 31, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 14,571 $ 1,031 $ 528,187 $ — $ 543,789 Accounts receivable, net 2,551 8,768 255,815 4,859 271,993 Accounts receivable from consolidated subsidiaries 4,861 2,176,059 309,149 (2,490,069 ) — Inventories, net — 200,852 140,406 (25,087 ) 316,171 Prepaid expenses and other current assets 14,239 5,332 17,474 3,337 40,382 Prepaid taxes — — 7,766 413 8,179 Assets held for sale — — 2,879 — 2,879 Total current assets 36,222 2,392,042 1,261,676 (2,506,547 ) 1,183,393 Property, plant and equipment, net 2,566 163,847 136,486 — 302,899 Goodwill — 708,546 568,174 — 1,276,720 Intangibles assets, net — 640,999 450,664 — 1,091,663 Deferred tax assets 73,051 — 5,185 (76,524 ) 1,712 Notes receivable and other amounts due from consolidated subsidiaries 1,387,615 2,085,538 — (3,473,153 ) — Other assets 6,044,337 1,525,285 29,962 (7,564,758 ) 34,826 Total assets $ 7,543,791 $ 7,516,257 $ 2,452,147 $ (13,620,982 ) $ 3,891,213 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 133,071 $ — $ 50,000 $ — $ 183,071 Accounts payable 4,540 30,924 33,936 — 69,400 Accounts payable to consolidated subsidiaries 2,242,814 214,203 33,052 (2,490,069 ) — Accrued expenses 16,827 18,126 30,196 — 65,149 Current portion of contingent consideration — 587 — — 587 Payroll and benefit-related liabilities 20,610 26,672 35,397 — 82,679 Accrued interest 10,429 — 21 — 10,450 Income taxes payable 1,246 — 6,577 85 7,908 Other current liabilities 2,262 3,643 2,497 — 8,402 Total current liabilities 2,431,799 294,155 191,676 (2,489,984 ) 427,646 Long-term borrowings 850,252 — — — 850,252 Deferred tax liabilities — 316,526 31,375 (76,524 ) 271,377 Pension and postretirement benefit liabilities 85,645 31,561 15,856 — 133,062 Noncurrent liability for uncertain tax positions 1,169 13,684 2,667 — 17,520 Notes payable and other amounts due to consolidated subsidiaries 2,011,737 1,264,004 197,412 (3,473,153 ) — Other liabilities 23,848 15,695 12,472 — 52,015 Total liabilities 5,404,450 1,935,625 451,458 (6,039,661 ) 1,751,872 Convertible notes - redeemable equity component 1,824 — — — 1,824 Mezzanine equity 1,824 — — — 1,824 Total shareholders' equity 2,137,517 5,580,632 2,000,689 (7,581,321 ) 2,137,517 Total liabilities and shareholders' equity $ 7,543,791 $ 7,516,257 $ 2,452,147 $ (13,620,982 ) $ 3,891,213
Condensed Consolidating Statements of Cash Flows	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Six Months Ended July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (121,726 ) $ 232,874 $ 148,460 $ (61,918 ) $ 197,690 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (173 ) (19,760 ) (16,900 ) — (36,833 ) Proceeds from sale of assets — — 6,332 — 6,332 Payments for businesses and intangibles acquired, net of cash acquired (975,524 ) — (17,935 ) — (993,459 ) Net cash used in investing activities from continuing operations (975,697 ) (19,760 ) (28,503 ) — (1,023,960 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 1,194,500 — — — 1,194,500 Reduction in borrowings (228,273 ) — — — (228,273 ) Debt extinguishment, issuance and amendment fees (19,114 ) — — — (19,114 ) Net proceeds from share based compensation plans and the related tax impacts 1,305 — — — 1,305 Payments for contingent consideration — (153 ) — — (153 ) Dividends paid (30,590 ) — — — (30,590 ) Intercompany transactions 222,684 (203,029 ) (19,655 ) — — Intercompany dividends paid — — (61,918 ) 61,918 — Net cash provided by (used in) financing activities from continuing operations 1,140,512 (203,182 ) (81,573 ) 61,918 917,675 Cash flows from discontinued operations: Net cash used in operating activities (961 ) — — — (961 ) Net cash used in discontinued operations (961 ) — — — (961 ) Effect of exchange rate changes on cash and cash equivalents — — 41,981 — 41,981 Net increase in cash and cash equivalents 42,128 9,932 80,365 132,425 Cash and cash equivalents at the beginning of the period 14,571 1,031 528,187 — 543,789 Cash and cash equivalents at the end of the period $ 56,699 $ 10,963 $ 608,552 $ — $ 676,214 Six Months Ended June 26, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (29,648 ) $ 69,875 $ 141,261 $ — $ 181,488 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (146 ) (9,947 ) (9,442 ) — (19,535 ) Proceeds from sale of assets — 20,642 1,251 (17,908 ) 3,985 Payments for businesses and intangibles acquired, net of cash acquired — — (21,025 ) 17,908 (3,117 ) Net cash (used in) provided by investing activities from continuing operations (146 ) 10,695 (29,216 ) — (18,667 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 665,000 — — — 665,000 Reduction in borrowings (656,479 ) — — — (656,479 ) Debt extinguishment, issuance and amendment fees (8,182 ) — — — (8,182 ) Net proceeds from share based compensation plans and the related tax impacts 6,593 — — — 6,593 Payments for contingent consideration — (133 ) — — (133 ) Dividends paid (28,998 ) — — — (28,998 ) Intercompany transactions 81,640 (79,348 ) (2,292 ) — — Net cash provided by (used in) financing activities from continuing operations 59,574 (79,481 ) (2,292 ) — (22,199 ) Cash flows from discontinued operations: Net cash used in operating activities (1,183 ) — — — (1,183 ) Net cash used in discontinued operations (1,183 ) — — — (1,183 ) Effect of exchange rate changes on cash and cash equivalents — — (1,315 ) — (1,315 ) Net increase in cash and cash equivalents 28,597 1,089 108,438 — 138,124 Cash and cash equivalents at the beginning of the period 21,612 — 316,754 — 338,366 Cash and cash equivalents at the end of the period $ 50,209 $ 1,089 $ 425,192 $ — $ 476,490

New accounting standards (Detai

New accounting standards (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase in net income and cash flows from operating activities due to adoption of new standard			$ 197,690	$ 181,488
Net income	$ 78,003	$ 59,303	$ 118,173	$ 109,992
Net income (in dollars per share)	$ 1.67	$ 1.26	$ 2.53	$ 2.29
Accounting Standards Update 2016-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income	$ 1,100		$ 4,500
Net income (in dollars per share)	$ 0.02		$ 0.09

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended
	Jul. 31, 2016USD ($)	Jul. 02, 2017USD ($)	Jun. 26, 2016business	Jul. 02, 2017USD ($)	Sep. 25, 2016USD ($)	Apr. 03, 2017USD ($)	Feb. 17, 2017USD ($)$ / shares	Jul. 01, 2016
Business Acquisition [Line Items]
Number of businesses acquired				2
Pyng [Member]
Business Acquisition [Line Items]
Net assets acquired						$ 17,900
Vascular Solutions, Inc.
Business Acquisition [Line Items]
Net assets acquired							$ 975,524
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets							$ 1,173,075
Business acquisition, share price (in dollars per share) | $ / shares							$ 56
Integration related costs				$ 8,200
Pro forma, revenue actual		$ 45,000		66,700
Pro forma, net income (loss) actual		$ 3,300		$ (11,600)
Teleflex Medical Private Limited
Business Acquisition [Line Items]
Ownership percentage								74.00%
Percentage of interests acquired								26.00%
Purchase price in excess of noncontrolling interest	$ 7,500
Medical Device and Supplies Distributors in New Zealand
Business Acquisition [Line Items]
Number of businesses acquired | business			2
2016 Acquisitions
Business Acquisition [Line Items]
Consideration transferred					$ 22,800
Intellectual property | Pyng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets						13,000
Customer lists | Pyng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets						$ 5,500

Acquisitions - Assets Acquired

Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jul. 02, 2017	Feb. 17, 2017	Dec. 31, 2016
Assets
Goodwill	$ 1,854,076		$ 1,276,720
Vascular Solutions, Inc.
Assets
Current assets		$ 63,867
Property, plant and equipment		46,616
Intangible assets		539,250
Goodwill		522,614
Other assets		728
Total assets acquired		1,173,075
Less:
Current liabilities		15,079
Deferred tax liabilities		182,472
Liabilities assumed		197,551
Net assets acquired		$ 975,524

Acquisitions - Schedule of Inta

Acquisitions - Schedule of Intangible Assets Acquired (Details) - Vascular Solutions, Inc. - USD ($) $ in Thousands	Feb. 17, 2017	Jul. 02, 2017	Jul. 02, 2017
Business Acquisition [Line Items]
Fair value	$ 539,250
Pro forma, revenue actual		$ 45,000	$ 66,700
Pro forma, net income (loss) actual		$ 3,300	$ (11,600)
Intellectual property
Business Acquisition [Line Items]
Fair value	$ 248,200
Intellectual property | Minimum
Business Acquisition [Line Items]
Useful life range	10 years
Intellectual property | Maximum
Business Acquisition [Line Items]
Useful life range	20 years
In-process research and development (IPR&D)
Business Acquisition [Line Items]
Fair value	$ 15,600
Trade names
Business Acquisition [Line Items]
Fair value	16,650
Useful life range			20 years
Customer lists
Business Acquisition [Line Items]
Fair value	$ 258,800
Useful life range			25 years

Acquisitions - Pro Forma (Detai

Acquisitions - Pro Forma (Details) - Vascular Solutions, Inc. - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Business Acquisition [Line Items]
Net revenue	$ 528,613	$ 514,574	$ 1,039,318	$ 978,697
Net income	$ 79,221	$ 59,352	$ 128,302	$ 77,252
Net Income, Basic earnings per common share (in USD per share)	$ 1.76	$ 1.36	$ 2.85	$ 1.81
Net Income, Diluted earnings per common share (in USD per share)	$ 1.69	$ 1.26	$ 2.75	$ 1.61
Basic, weighted average common shares outstanding (in shares)	44,996	43,549	44,945	42,598
Diluted, weighted average common shares outstanding (in shares)	46,818	47,246	46,716	48,014

Restructuring charges - Charges

Restructuring charges - Charges Recognized (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 870	$ (119)	$ 13,815	$ 9,849
Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	612	(609)	13,361	9,243
Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	35	55	94	178
Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	75	115	134	7
Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	148	320	226	421
2017 Vascular Solutions integration program
Restructuring Cost and Reserve [Line Items]
Restructuring charges	404		4,887
2017 Vascular Solutions integration program | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	370		4,853
2017 Vascular Solutions integration program | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0		0
2017 Vascular Solutions integration program | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0		0
2017 Vascular Solutions integration program | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	34		34
2017 EMEA restructuring program
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(584)		6,536
2017 EMEA restructuring program | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(584)		6,536
2017 EMEA restructuring program | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0		0
2017 EMEA restructuring program | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0		0
2017 EMEA restructuring program | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0		0
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	391		901
2016 Footprint realignment plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	286		825
2016 Footprint realignment plan | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	10		22
2016 Footprint realignment plan | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(4)		(75)
2016 Footprint realignment plan | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	99		129
2015 Restructuring programs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		(247)		(10)
2015 Restructuring programs | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges		(442)		(399)
2015 Restructuring programs | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		55		178
2015 Restructuring programs | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		115		93
2015 Restructuring programs | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		25		118
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(114)		197
2014 Footprint realignment plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(121)		182
2014 Footprint realignment plan | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	14		14
2014 Footprint realignment plan | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0		0
2014 Footprint realignment plan | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(7)		1
Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	773		1,294	(80)
Other restructuring programs | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	661		965	0
Other restructuring programs | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	11		58	0
Other restructuring programs | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	79		209	(86)
Other restructuring programs | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 22		$ 62	6
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges		7		10,354
2016 Footprint realignment plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges		(279)		10,068
2016 Footprint realignment plan | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		0		0
2016 Footprint realignment plan | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		0		0
2016 Footprint realignment plan | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		286		286
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges		121		(415)
2014 Footprint realignment plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges		112		(426)
2014 Footprint realignment plan | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		0		0
2014 Footprint realignment plan | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		0		0
2014 Footprint realignment plan | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 9		$ 11

Restructuring charges - Additio

Restructuring charges - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
2017 Vascular Solutions integration program | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 6		$ 6
2017 Vascular Solutions integration program | Minimum | Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	4.5		4.5
2017 Vascular Solutions integration program | Minimum | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	1.5		1.5
2017 Vascular Solutions integration program | Minimum | Retention Bonuses
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	2.5		2.5
2017 Vascular Solutions integration program | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	7.5		7.5
2017 Vascular Solutions integration program | Maximum | Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	5.3		5.3
2017 Vascular Solutions integration program | Maximum | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	2.2		2.2
2017 Vascular Solutions integration program | Maximum | Retention Bonuses
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	3		3
2017 EMEA restructuring program | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	7.1		7.1
2017 EMEA restructuring program | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	8.5		8.5
2016 Other Restructuring programs
Restructuring Cost and Reserve [Line Items]
Restructuring costs expected cash payment	1		1
Restructuring reserve	1.2		1.2
2016 Other Restructuring programs | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	1.5		1.5
2016 Other Restructuring programs | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	3.8		3.8
2016 Other Restructuring programs | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	4.7		4.7
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	8.7		8.7
Aggregate restructuring charges incurred	13.4		13.4
2016 Footprint realignment plan | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	2	$ 1.8	4.1	$ 2.4
Aggregate restructuring charges incurred	10.5		10.5
2016 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	34		34
Restructuring costs expected cash payment	27		27
2016 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	44		44
Restructuring costs expected cash payment	31		31
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	4.5		4.5
Restructuring expenses			25
Aggregate restructuring charges incurred	11.3		11.3
2014 Footprint realignment plan | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	0.5	$ 2.3	2.1	$ 4.4
2014 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	43		43
Restructuring costs expected cash payment	33		33
Expected capital expenditures	24		24
2014 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	48		48
Restructuring costs expected cash payment	38		38
Expected capital expenditures	$ 30		$ 30

Restructuring charges - Charg44

Restructuring charges - Charges by segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 870	$ (119)	$ 13,815	$ 9,849
Vascular North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	361	351	1,109	4,514
Anesthesia North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	564	364	811	2,239
Surgical North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	0	0	(20)
EMEA
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(365)	(949)	7,135	2,923
Asia
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	(2)	0	0
OEM
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	(1)	0	4
All Other
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 310	$ 118	$ 4,760	$ 189

Inventories, net (Detail)

Inventories, net (Detail) - USD ($) $ in Thousands	Jul. 02, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 94,924	$ 65,319
Work-in-process	61,561	54,555
Finished goods	212,041	196,297
Inventories, net	$ 368,526	$ 316,171

Goodwill and other intangible46

Goodwill and other intangible assets, net - Changes in carrying amount of goodwill, by reporting segment (Details) $ in Thousands	6 Months Ended
	Jul. 02, 2017USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 1,276,720
Goodwill related to acquisitions	535,609
Currency translation and other adjustments	41,747
Goodwill, ending balance	1,854,076
Vascular North America
Goodwill [Roll Forward]
Goodwill, beginning balance	345,546
Goodwill related to acquisitions	0
Currency translation and other adjustments	(1,590)
Goodwill, ending balance	343,956
Anesthesia North America
Goodwill [Roll Forward]
Goodwill, beginning balance	141,253
Goodwill related to acquisitions	5,426
Currency translation and other adjustments	215
Goodwill, ending balance	146,894
Surgical North America
Goodwill [Roll Forward]
Goodwill, beginning balance	250,912
Goodwill related to acquisitions	0
Currency translation and other adjustments	0
Goodwill, ending balance	250,912
EMEA
Goodwill [Roll Forward]
Goodwill, beginning balance	290,041
Goodwill related to acquisitions	6,010
Currency translation and other adjustments	24,729
Goodwill, ending balance	320,780
Asia
Goodwill [Roll Forward]
Goodwill, beginning balance	138,185
Goodwill related to acquisitions	1,559
Currency translation and other adjustments	6,217
Goodwill, ending balance	145,961
OEM
Goodwill [Roll Forward]
Goodwill, beginning balance	4,883
Goodwill related to acquisitions	0
Currency translation and other adjustments	0
Goodwill, ending balance	4,883
All Other
Goodwill [Roll Forward]
Goodwill, beginning balance	105,900
Goodwill related to acquisitions	522,614
Currency translation and other adjustments	12,176
Goodwill, ending balance	$ 640,690

Goodwill and other intangible47

Goodwill and other intangible assets, net - Components of intangible assets (Details) - USD ($) $ in Thousands	Jul. 02, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,132,784	$ 1,564,359
Accumulated Amortization	(519,880)	(472,696)
In-process research and development
Finite-Lived Intangible Assets [Line Items]
In-process research and development	33,595	16,532
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	892,574	622,428
Accumulated Amortization	(259,002)	(239,055)
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	774,980	519,962
Accumulated Amortization	(226,354)	(203,390)
Distribution rights
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	23,452	23,021
Accumulated Amortization	(16,208)	(15,239)
Trade names
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	405,283	379,724
Accumulated Amortization	(16,862)	(13,974)
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	2,900	2,692
Accumulated Amortization	$ (1,454)	$ (1,038)

Borrowings - Components of long

Borrowings - Components of long-term debt (Details) - USD ($) $ in Thousands	6 Months Ended
	Jul. 02, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Total borrowings	$ 2,012,303	$ 1,046,076
Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017	(126)	(2,707)
Less: Unamortized debt issuance costs	(12,422)	(10,046)
Total long-term debt	1,999,755	1,033,323
Current borrowings	(112,039)	(183,071)
Long-term borrowings	1,887,716	850,252
Revolving Credit Facility
Debt Instrument [Line Items]
Senior Credit Facility:	$ 547,000	210,000
Line of credit facility interest rate	3.22%
Term Loan
Debt Instrument [Line Items]
Senior Credit Facility:	$ 721,000	0
Line of credit facility interest rate	3.22%
Senior Notes | 3.875% Convertible Senior Subordinated Notes due 2017
Debt Instrument [Line Items]
3.875% Convertible Senior Subordinated Notes due 2017	$ 44,303	136,076
Debt instrument, stated interest rate	3.875%
Senior Notes | 4.875% Senior Notes due 2026
Debt Instrument [Line Items]
Senior Notes	$ 400,000	400,000
Debt instrument, stated interest rate	4.875%
Senior Notes | 5.25% Senior Notes due 2024
Debt Instrument [Line Items]
Senior Notes	$ 250,000	250,000
Debt instrument, stated interest rate	5.25%
Securitization program, at a rate of 1.97% at July 2, 2017
Debt Instrument [Line Items]
Securitization program, at a rate of 1.97% at July 2, 2017	$ 50,000	$ 50,000
Debt instrument, stated interest rate	1.97%

Borrowings - Amended and restat

Borrowings - Amended and restated credit facility (Details)	Jan. 20, 2017USD ($)	Jul. 02, 2017USD ($)	Apr. 02, 2017USD ($)	Jun. 26, 2016USD ($)	Jul. 02, 2017USD ($)	Jun. 26, 2016USD ($)
Line of Credit Facility [Line Items]
Loss on extinguishment of debt		$ 11,000		$ 19,261,000	$ 5,593,000	$ 19,261,000
2017 Credit Agreement
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	2.00%
Maximum leverage ratio	4.50
Maximum secured leverage ratio	3.50
Minimum interest coverage ratio	3.50
Line of credit, debt issuance cost		$ 12,000,000			$ 12,000,000
2017 Credit Agreement | Revolving Credit Facility
Line of Credit Facility [Line Items]
Debt instrument term	5 years
Maximum borrowing capacity	$ 1,000,000,000
2017 Credit Agreement | Term Loan
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 750,000,000
2013 Credit Agreement
Line of Credit Facility [Line Items]
Loss on extinguishment of debt			$ 400,000
London Interbank Offered Rate (LIBOR) | Minimum | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.25%
London Interbank Offered Rate (LIBOR) | Maximum | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	2.50%
Federal Funds Effective Swap Rate | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	0.50%
Adjusted LIBOR | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.00%
Adjusted LIBOR | Minimum | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	0.25%
Adjusted LIBOR | Maximum | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.50%

Borrowings - 3.875% Convertible

Borrowings - 3.875% Convertible Senior Subordinated Notes (Details) - USD ($) shares in Thousands	Jan. 05, 2017	Jul. 02, 2017	Apr. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Short-term Debt [Line Items]
Repayments of debt					$ 228,273,000	$ 656,479,000
Conversion of convertible notes, shares issued upon conversion		500		1,500	400	2,200
Loss on extinguishment of debt		$ 11,000		$ 19,261,000	$ 5,593,000	$ 19,261,000
Shares delivered to the company by the counterparties to the convertible note hedge transactions					120
3.875% Convertible Senior Subordinated Notes due 2017 | Senior Notes
Short-term Debt [Line Items]
Extinguishment of debt, amount	$ 91,700,000
Principal amount of convertible debt	1,000
Repayments of debt	93,200,000
Repayments of debt, accrued interest	$ 1,500,000
Conversion of convertible notes, shares issued upon conversion	930
Loss on extinguishment of debt			$ 5,200,000
Convertible Debt [Member] | Convertible Notes Payable [Member] | Conversion [Member]
Short-term Debt [Line Items]
Conversion of convertible notes, shares issued upon conversion					500
Shares delivered to the company by the counterparties to the convertible note hedge transactions					500
Short-term Debt		44,300,000			$ 44,300,000
Aggregate principal amount of Convertible Notes tendered to the Company for conversion		$ 44,200,000			$ 44,200,000

Borrowings - Fair value of long

Borrowings - Fair value of long term debt (Details) - USD ($) $ in Thousands	Jul. 02, 2017	Dec. 31, 2016
Fair Value Measurements [Line Items]
Fair value of debt	$ 2,133,492	$ 1,274,127
Level 1
Fair Value Measurements [Line Items]
Fair value of debt	149,676	344,765
Level 2
Fair Value Measurements [Line Items]
Fair value of debt	$ 1,983,816	$ 929,362

Financial instruments - Additio

Financial instruments - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016	Dec. 31, 2016
Derivatives Fair Value [Line Items]
Net revenues	$ 528,613,000	$ 473,553,000	$ 1,016,494,000	$ 898,446,000
Spain, Italy, Portugal, and Greece
Derivatives Fair Value [Line Items]
Net revenues			64,500,000	63,700,000
Cash flow hedging
Derivatives Fair Value [Line Items]
Ineffectiveness related to derivatives	0	0	0	0
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts	73,600,000		73,600,000		$ 101,800,000
Foreign exchange contract | Not Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Loss related to currency forward contracts	2,300,000	$ 1,300,000	3,100,000	$ 1,600,000
Total notional amount for all open foreign currency forward contracts	$ 92,200,000		$ 92,200,000		$ 73,400,000

Financial instruments - Fair va

Financial instruments - Fair values of derivative instruments designated as hedging instruments (Details) - USD ($) $ in Thousands	Jul. 02, 2017	Dec. 31, 2016
Derivatives Fair Value [Line Items]
Total asset derivatives	$ 2,880	$ 1,157
Total liability derivatives	489	2,257
Foreign exchange contract | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	2,880	1,157
Foreign exchange contract | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	489	2,257
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	2,590	667
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	323	2,139
Foreign exchange contract | Not Designated as Hedging Instrument | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	290	490
Foreign exchange contract | Not Designated as Hedging Instrument | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	$ 166	$ 118

Financial instruments - Aggrega

Financial instruments - Aggregate accounts receivable, net of allowance for doubtful accounts (Details) - USD ($) $ in Thousands	1 Months Ended
	Jan. 31, 2017	Jul. 02, 2017	Dec. 31, 2016
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts receivable		$ 9,813	$ 8,630
Allowance for doubtful accounts		2,700	2,000
Spain, Italy, Portugal, and Greece
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current and long-term trade accounts receivable in Greece, Italy, Spain and Portugal		$ 51,896	$ 51,098
Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal		17.50%	19.30%
Long-term portion of accounts receivable, net		$ 3,000	$ 2,700
Italy
Accounts, Notes, Loans and Financing Receivable [Line Items]
Financing receivable, significant sales	$ 16,100
Proceeds from sale of receivables	$ 16,000

Fair value measurement - Financ

Fair value measurement - Financial assets and liabilities carried at fair value measured on recurring basis (Details) - USD ($) $ in Thousands	Jul. 02, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	$ 8,252	$ 7,660
Derivative assets	2,880	1,157
Derivative liabilities	489	2,257
Contingent consideration liabilities	6,712	7,102
Current portion of contingent consideration	584	587
Fair value measurement with unobservable inputs reconciliations other liabilities	6,100	6,500
Quoted prices in active markets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	8,252	7,660
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	0	0
Significant other observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	2,880	1,157
Derivative liabilities	489	2,257
Contingent consideration liabilities	0	0
Significant unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	$ 6,712	$ 7,102

Fair value measurement - Reconc

Fair value measurement - Reconciliation of changes in financial liabilities measured on recurring basis (Details) $ in Thousands	6 Months Ended
	Jul. 02, 2017USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 7,102
Payment	(153)
Revaluations	(237)
Ending balance	$ 6,712

Shareholders' equity - Addition

Shareholders' equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	3 Months Ended			6 Months Ended
	Jul. 02, 2017	Apr. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016	Dec. 31, 2016
Shareholders Equity [Line Items]
Investment warrants, exercise price (in dollars per share)		$ 74.65
Conversion of convertible notes, shares issued upon conversion	0.5		1.5	0.4	2.2
Convertible notes - redeemable equity component	$ 0			$ 0		$ 1,824
Equity Option
Shareholders Equity [Line Items]
Weighted average antidilutive shares which were not included in the calculation of earnings per share	0.7		5	0.6	5.1
Convertible Note
Shareholders Equity [Line Items]
Weighted average antidilutive shares which were not included in the calculation of earnings per share	0.5		1.7	0.5	2.6

Shareholders' equity - Reconcil

Shareholders' equity - Reconciliation of basic to diluted weighted average common shares outstanding (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Debt Instrument [Line Items]
Basic (in shares)	44,996	43,549	44,945	42,598
Dilutive effect of share-based awards (in shares)	866	566	843	543
Dilutive effect of 3.875% Convertible Notes and warrants (in shares)	956	3,131	928	4,873
Diluted (in shares)	46,818	47,246	46,716	48,014
Senior Notes | 3.875% Convertible Senior Subordinated Notes due 2017
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.875%		3.875%

Shareholders' equity - Change i

Shareholders' equity - Change in accumulated other comprehensive income, net of tax (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			$ 2,137,517
Other comprehensive income (loss) before reclassifications			114,682	$ 9,976
Amounts reclassified from accumulated other comprehensive income	$ 2,231	$ 2,191	4,740	4,777
Net current-period other comprehensive income			119,422	14,753
Ending Balance	2,358,529		2,358,529
Cash Flow Hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(2,424)	(2,491)
Other comprehensive income (loss) before reclassifications			2,684	(1,684)
Amounts reclassified from accumulated other comprehensive income			2,477	2,668
Net current-period other comprehensive income			5,161	984
Ending Balance	2,737	(1,507)	2,737	(1,507)
Pension and Other Postretirement Benefit Plans
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(136,596)	(138,887)
Other comprehensive income (loss) before reclassifications			(669)	375
Amounts reclassified from accumulated other comprehensive income	1,132	1,053	2,263	2,109
Net current-period other comprehensive income			1,594	2,484
Ending Balance	(135,002)	(136,403)	(135,002)	(136,403)
Foreign Currency Translation Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(299,697)	(229,746)
Other comprehensive income (loss) before reclassifications			112,667	11,285
Amounts reclassified from accumulated other comprehensive income			0	0
Net current-period other comprehensive income			112,667	11,285
Ending Balance	(187,030)	(218,461)	(187,030)	(218,461)
Accumulated Other Comprehensive (Loss) Income
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(438,717)	(371,124)
Ending Balance	$ (319,295)	$ (356,371)	$ (319,295)	$ (356,371)

Shareholders' equity - Accumula

Shareholders' equity - Accumulated other comprehensive income into income expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	$ (238,329)	$ (217,154)	$ (470,650)	$ (416,900)
Total before tax	(90,458)	(67,402)	(128,138)	(121,195)
Taxes on income from continuing operations	12,095	8,007	9,426	10,620
Net of tax	(78,363)	(59,395)	(118,712)	(110,575)
Total reclassifications, net of tax	2,231	2,191	4,740	4,777
Actuarial losses
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,727	1,620	3,453	3,242
Prior-service costs
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	30	14	59	28
Pension and Other Postretirement Benefits Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,757	1,634	3,512	3,270
Tax benefit	(625)	(581)	(1,249)	(1,161)
Total reclassifications, net of tax	1,132	1,053	2,263	2,109
Reclassification out of Accumulated Other Comprehensive Income [Member] | Foreign exchange contract | Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	1,303	1,501	2,948	3,372
Total before tax	1,303	1,501	2,948	3,372
Taxes on income from continuing operations	(204)	(363)	(471)	(704)
Net of tax	$ 1,099	$ 1,138	$ 2,477	$ 2,668

Taxes on income from continui61

Taxes on income from continuing operations (Details)	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Income Tax Disclosure [Abstract]
Effective income tax rate	13.40%	11.90%	7.40%	8.80%

Pension and other postretirem62

Pension and other postretirement benefits (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Pension
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 720	$ 655	$ 1,437	$ 1,307
Interest cost	3,789	3,929	7,574	7,849
Expected return on plan assets	(6,750)	(6,199)	(13,493)	(12,397)
Net amortization and deferral	1,691	1,577	3,381	3,156
Net benefits expense (income)	(550)	(38)	(1,101)	(85)
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	75	111	149	222
Interest cost	379	407	757	813
Expected return on plan assets	0	0	0	0
Net amortization and deferral	66	57	131	114
Net benefits expense (income)	$ 520	$ 575	$ 1,037	$ 1,149

Commitments and contingent li63

Commitments and contingent liabilities (Detail) ¥ in Millions, $ in Millions	Mar. 24, 2017USD ($)	Mar. 24, 2017CNY (¥)	Dec. 05, 2014USD ($)	Jul. 02, 2017USD ($)
Loss Contingencies [Line Items]
Estimated litigation liability				$ 2.5
Minimum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out				15 years
Maximum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out				20 years
Accrued Liabilities
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies				$ 1.1
Other Liability
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies				5.5
Discontinued Operations
Loss Contingencies [Line Items]
Estimated litigation liability				1.7
Distributor vs Teleflex Medical Trading Company, Ltd.
Loss Contingencies [Line Items]
Damages sought	$ 7.5	¥ 51.2
Distributor vs Teleflex Medical Trading Company, Ltd. Repurchase of Inventory
Loss Contingencies [Line Items]
Damages sought	14.4	97.5
Teleflex Medical Trading Company, Ltd. vs Distributor - Outstanding Receivables
Loss Contingencies [Line Items]
Damages sought	$ 9	¥ 61.2
Compensatory Damages | Judicial Ruling | Parish of Calcasieu
Loss Contingencies [Line Items]
Damages awarded			$ 0.1
Punitive Damages | Judicial Ruling | Parish of Calcasieu
Loss Contingencies [Line Items]
Damages awarded			$ 23
Unfavorable Regulatory Action | Judicial Ruling | Parish of Calcasieu | Maximum
Loss Contingencies [Line Items]
Estimate of possible loss				$ 10

Segment information (Details)

Segment information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 528,613	$ 473,553	$ 1,016,494	$ 898,446
Operating profit	110,202	98,441	171,021	165,938
Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	126,519	111,738	217,100	201,810
Unallocated expenses
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	(16,317)	(13,297)	(46,079)	(35,872)
Vascular North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	93,522	88,111	187,371	169,699
Vascular North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	25,258	21,994	50,074	41,650
Anesthesia North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	49,081	49,194	97,288	95,151
Anesthesia North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	20,516	15,050	34,043	27,227
Surgical North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	44,716	43,136	90,660	82,077
Surgical North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	17,287	12,348	33,667	25,604
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	131,962	131,705	262,695	253,800
EMEA | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	23,250	23,944	45,490	44,987
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	63,988	63,191	112,941	112,347
Asia | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	18,604	21,751	29,402	34,759
OEM
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	45,132	40,298	88,478	74,275
OEM | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	10,337	9,215	19,458	14,404
All other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	100,212	57,918	177,061	111,097
All other | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	$ 11,267	$ 7,436	$ 4,966	$ 13,179

Condensed consolidating guara65

Condensed consolidating guarantor financial information - Additional Information (Detail) - Senior Notes	Jul. 02, 2017
5.25% Senior Notes due 2024
Condensed Financial Statements Captions [Line Items]
Debt instrument, stated interest rate	5.25%
Ownership percentage	100.00%
4.875% Senior Notes due 2026
Condensed Financial Statements Captions [Line Items]
Debt instrument, stated interest rate	4.875%

Condensed consolidating guara66

Condensed consolidating guarantor financial information - Income and Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016	Jul. 02, 2017	Jun. 26, 2016
Condensed Income Statements, Captions [Line Items]
Net revenues	$ 528,613	$ 473,553	$ 1,016,494	$ 898,446
Cost of goods sold	238,329	217,154	470,650	416,900
Gross profit	290,284	256,399	545,844	481,546
Selling, general and administrative expenses	158,934	142,983	322,903	279,331
Research and development expenses	20,278	15,472	38,105	27,825
Restructuring charges	870	(119)	13,815	9,849
Gain on sale of assets	0	(378)	0	(1,397)
Income from continuing operations before interest, loss on extinguishment of debt and taxes	110,202	98,441	171,021	165,938
Interest, net	19,733	11,778	37,290	25,482
Loss on extinguishment of debt	11	19,261	5,593	19,261
Income from continuing operations before taxes	90,458	67,402	128,138	121,195
(Benefit) taxes on (loss) income from continuing operations	12,095	8,007	9,426	10,620
Equity in net income of consolidated subsidiaries	0	0	0	0
Income from continuing operations	78,363	59,395	118,712	110,575
Operating loss from discontinued operations	(566)	6	(848)	(376)
Benefit on loss from discontinued operations	(206)	(187)	(309)	(257)
Income (loss) from discontinued operations	(360)	193	(539)	(119)
Net income	78,003	59,588	118,173	110,456
Less: Income from continuing operations attributable to noncontrolling interest	0	285	0	464
Net income	78,003	59,303	118,173	109,992
Other comprehensive income	69,822	(8,441)	119,422	14,753
Comprehensive income attributable to common shareholders	147,825	50,862	237,595	124,745
Reportable Legal Entities | Parent Company
Condensed Income Statements, Captions [Line Items]
Net revenues	0	0	0	0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expenses	7,468	10,285	27,987	19,614
Research and development expenses	264	140	499	140
Restructuring charges	0	0	0	0
Gain on sale of assets		0		0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	(7,732)	(10,425)	(28,486)	(19,754)
Interest, net	51,073	33,146	98,747	66,190
Loss on extinguishment of debt	11	19,261	5,593	19,261
Income from continuing operations before taxes	(58,816)	(62,832)	(132,826)	(105,205)
(Benefit) taxes on (loss) income from continuing operations	(23,115)	(23,077)	(53,022)	(38,925)
Equity in net income of consolidated subsidiaries	114,064	99,295	198,516	176,752
Income from continuing operations	78,363	59,540	118,712	110,472
Operating loss from discontinued operations	(566)	(373)	(848)	(755)
Benefit on loss from discontinued operations	(206)	(136)	(309)	(275)
Income (loss) from discontinued operations	(360)	(237)	(539)	(480)
Net income	78,003	59,303	118,173	109,992
Less: Income from continuing operations attributable to noncontrolling interest		0		0
Net income		59,303		109,992
Other comprehensive income	69,822	(8,441)	119,422	14,753
Comprehensive income attributable to common shareholders	147,825	50,862	237,595	124,745
Reportable Legal Entities | Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	338,620	280,430	654,263	539,341
Cost of goods sold	190,202	170,700	382,203	326,241
Gross profit	148,418	109,730	272,060	213,100
Selling, general and administrative expenses	95,171	86,385	189,214	167,862
Research and development expenses	13,594	8,644	24,780	15,079
Restructuring charges	1,335	557	6,709	5,315
Gain on sale of assets		(378)		(378)
Income from continuing operations before interest, loss on extinguishment of debt and taxes	38,318	14,522	51,357	25,222
Interest, net	(32,421)	(22,437)	(63,384)	(42,755)
Loss on extinguishment of debt	0	0	0	0
Income from continuing operations before taxes	70,739	36,959	114,741	67,977
(Benefit) taxes on (loss) income from continuing operations	22,123	14,504	36,608	26,181
Equity in net income of consolidated subsidiaries	58,861	63,605	114,663	121,505
Income from continuing operations	107,477	86,060	192,796	163,301
Operating loss from discontinued operations	0	0	0	0
Benefit on loss from discontinued operations	0	0	0	0
Income (loss) from discontinued operations	0	0	0	0
Net income	107,477	86,060	192,796	163,301
Less: Income from continuing operations attributable to noncontrolling interest		0		0
Net income		86,060		163,301
Other comprehensive income	68,127	(9,685)	117,531	8,888
Comprehensive income attributable to common shareholders	175,604	76,375	310,327	172,189
Reportable Legal Entities | Non-Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	296,977	290,784	573,292	552,132
Cost of goods sold	152,440	146,997	296,336	279,960
Gross profit	144,537	143,787	276,956	272,172
Selling, general and administrative expenses	56,334	46,297	105,178	91,356
Research and development expenses	6,420	6,688	12,826	12,606
Restructuring charges	(465)	(676)	7,106	4,534
Gain on sale of assets		0		(1,019)
Income from continuing operations before interest, loss on extinguishment of debt and taxes	82,248	91,478	151,846	164,695
Interest, net	1,081	1,069	1,927	2,047
Loss on extinguishment of debt	0	0	0	0
Income from continuing operations before taxes	81,167	90,409	149,919	162,648
(Benefit) taxes on (loss) income from continuing operations	14,210	15,909	26,439	23,773
Equity in net income of consolidated subsidiaries	240	175	456	343
Income from continuing operations	67,197	74,675	123,936	139,218
Operating loss from discontinued operations	0	379	0	379
Benefit on loss from discontinued operations	0	(51)	0	18
Income (loss) from discontinued operations	0	430	0	361
Net income	67,197	75,105	123,936	139,579
Less: Income from continuing operations attributable to noncontrolling interest		285		464
Net income		74,820		139,115
Other comprehensive income	69,374	(11,378)	123,275	11,034
Comprehensive income attributable to common shareholders	136,571	63,442	247,211	150,149
Eliminations
Condensed Income Statements, Captions [Line Items]
Net revenues	(106,984)	(97,661)	(211,061)	(193,027)
Cost of goods sold	(104,313)	(100,543)	(207,889)	(189,301)
Gross profit	(2,671)	2,882	(3,172)	(3,726)
Selling, general and administrative expenses	(39)	16	524	499
Research and development expenses	0	0	0	0
Restructuring charges	0	0	0	0
Gain on sale of assets		0		0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	(2,632)	2,866	(3,696)	(4,225)
Interest, net	0	0	0	0
Loss on extinguishment of debt	0	0	0	0
Income from continuing operations before taxes	(2,632)	2,866	(3,696)	(4,225)
(Benefit) taxes on (loss) income from continuing operations	(1,123)	671	(599)	(409)
Equity in net income of consolidated subsidiaries	(173,165)	(163,075)	(313,635)	(298,600)
Income from continuing operations	(174,674)	(160,880)	(316,732)	(302,416)
Operating loss from discontinued operations	0	0	0	0
Benefit on loss from discontinued operations	0	0	0	0
Income (loss) from discontinued operations	0	0	0	0
Net income	(174,674)	(160,880)	(316,732)	(302,416)
Less: Income from continuing operations attributable to noncontrolling interest		0		0
Net income		(160,880)		(302,416)
Other comprehensive income	(137,501)	21,063	(240,806)	(19,922)
Comprehensive income attributable to common shareholders	$ (312,175)	$ (139,817)	$ (557,538)	$ (322,338)

Condensed consolidating guara67

Condensed consolidating guarantor financial information - Balance Sheets (Details) - USD ($) $ in Thousands	Jul. 02, 2017	Dec. 31, 2016	Jun. 26, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 676,214	$ 543,789	$ 476,490	$ 338,366
Accounts receivable, net	303,702	271,993
Accounts receivable from consolidated subsidiaries	0	0
Inventories, net	368,526	316,171
Prepaid expenses and other current assets	47,298	40,382
Prepaid taxes	11,878	8,179
Assets held for sale	0	2,879
Total current assets	1,407,618	1,183,393
Property, plant and equipment, net	369,301	302,899
Goodwill	1,854,076	1,276,720
Intangible assets, net	1,612,904	1,091,663
Deferred tax assets	1,963	1,712
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	44,162	34,826
Total assets	5,290,024	3,891,213
Current liabilities
Current borrowings	112,039	183,071
Accounts payable	81,973	69,400
Accounts payable to consolidated subsidiaries	0	0
Accrued expenses	85,050	65,149
Current portion of contingent consideration	584	587
Payroll and benefit-related liabilities	78,951	82,679
Accrued interest	5,294	10,450
Income taxes payable	3,438	7,908
Other current liabilities	8,722	8,402
Total current liabilities	376,051	427,646
Long-term borrowings	1,887,716	850,252
Deferred tax liabilities	468,034	271,377
Pension and postretirement benefit liabilities	128,335	133,062
Noncurrent liability for uncertain tax positions	18,378	17,520
Notes payable and other amounts due to consolidated subsidiaries	0	0
Other liabilities	52,981	52,015
Total liabilities	2,931,495	1,751,872
Convertible notes - redeemable equity component	0	1,824
Mezzanine equity	0	1,824
Total shareholders' equity	2,358,529	2,137,517
Total liabilities and shareholders' equity	5,290,024	3,891,213
Reportable Legal Entities | Parent Company
Current assets
Cash and cash equivalents	56,699	14,571	50,209	21,612
Accounts receivable, net	2,236	2,551
Accounts receivable from consolidated subsidiaries	8,333	4,861
Inventories, net	0	0
Prepaid expenses and other current assets	14,163	14,239
Prepaid taxes	4,490	0
Assets held for sale		0
Total current assets	85,921	36,222
Property, plant and equipment, net	2,398	2,566
Goodwill	0	0
Intangible assets, net	0	0
Deferred tax assets	72,037	73,051
Notes receivable and other amounts due from consolidated subsidiaries	1,310,464	1,387,615
Other assets	7,386,675	6,044,337
Total assets	8,857,495	7,543,791
Current liabilities
Current borrowings	62,039	133,071
Accounts payable	3,136	4,540
Accounts payable to consolidated subsidiaries	2,306,666	2,242,814
Accrued expenses	19,284	16,827
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	17,855	20,610
Accrued interest	5,264	10,429
Income taxes payable	0	1,246
Other current liabilities	500	2,262
Total current liabilities	2,414,744	2,431,799
Long-term borrowings	1,887,716	850,252
Deferred tax liabilities	0	0
Pension and postretirement benefit liabilities	80,154	85,645
Noncurrent liability for uncertain tax positions	1,729	1,169
Notes payable and other amounts due to consolidated subsidiaries	2,089,600	2,011,737
Other liabilities	25,023	23,848
Total liabilities	6,498,966	5,404,450
Convertible notes - redeemable equity component		1,824
Mezzanine equity		1,824
Total shareholders' equity	2,358,529	2,137,517
Total liabilities and shareholders' equity	8,857,495	7,543,791
Reportable Legal Entities | Guarantor Subsidiaries
Current assets
Cash and cash equivalents	10,963	1,031	1,089	0
Accounts receivable, net	34,592	8,768
Accounts receivable from consolidated subsidiaries	2,265,552	2,176,059
Inventories, net	228,022	200,852
Prepaid expenses and other current assets	9,280	5,332
Prepaid taxes	0	0
Assets held for sale		0
Total current assets	2,548,409	2,392,042
Property, plant and equipment, net	212,907	163,847
Goodwill	1,238,551	708,546
Intangible assets, net	1,152,095	640,999
Deferred tax assets	0	0
Notes receivable and other amounts due from consolidated subsidiaries	2,163,757	2,085,538
Other assets	1,706,244	1,525,285
Total assets	9,021,963	7,516,257
Current liabilities
Current borrowings	0	0
Accounts payable	38,529	30,924
Accounts payable to consolidated subsidiaries	261,263	214,203
Accrued expenses	26,593	18,126
Current portion of contingent consideration	584	587
Payroll and benefit-related liabilities	26,071	26,672
Accrued interest	0	0
Income taxes payable	0	0
Other current liabilities	4,250	3,643
Total current liabilities	357,290	294,155
Long-term borrowings	0	0
Deferred tax liabilities	508,629	316,526
Pension and postretirement benefit liabilities	31,026	31,561
Noncurrent liability for uncertain tax positions	13,781	13,684
Notes payable and other amounts due to consolidated subsidiaries	1,185,791	1,264,004
Other liabilities	13,961	15,695
Total liabilities	2,110,478	1,935,625
Convertible notes - redeemable equity component		0
Mezzanine equity		0
Total shareholders' equity	6,911,485	5,580,632
Total liabilities and shareholders' equity	9,021,963	7,516,257
Reportable Legal Entities | Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	608,552	528,187	425,192	316,754
Accounts receivable, net	262,539	255,815
Accounts receivable from consolidated subsidiaries	345,901	309,149
Inventories, net	168,954	140,406
Prepaid expenses and other current assets	20,518	17,474
Prepaid taxes	7,760	7,766
Assets held for sale		2,879
Total current assets	1,414,224	1,261,676
Property, plant and equipment, net	153,996	136,486
Goodwill	615,525	568,174
Intangible assets, net	460,809	450,664
Deferred tax assets	5,435	5,185
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	31,051	29,962
Total assets	2,681,040	2,452,147
Current liabilities
Current borrowings	50,000	50,000
Accounts payable	40,308	33,936
Accounts payable to consolidated subsidiaries	51,857	33,052
Accrued expenses	39,173	30,196
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	35,025	35,397
Accrued interest	30	21
Income taxes payable	4,408	6,577
Other current liabilities	3,972	2,497
Total current liabilities	224,773	191,676
Long-term borrowings	0	0
Deferred tax liabilities	34,914	31,375
Pension and postretirement benefit liabilities	17,155	15,856
Noncurrent liability for uncertain tax positions	2,868	2,667
Notes payable and other amounts due to consolidated subsidiaries	198,830	197,412
Other liabilities	13,997	12,472
Total liabilities	492,537	451,458
Convertible notes - redeemable equity component		0
Mezzanine equity		0
Total shareholders' equity	2,188,503	2,000,689
Total liabilities and shareholders' equity	2,681,040	2,452,147
Eliminations
Current assets
Cash and cash equivalents	0	0	$ 0	$ 0
Accounts receivable, net	4,335	4,859
Accounts receivable from consolidated subsidiaries	(2,619,786)	(2,490,069)
Inventories, net	(28,450)	(25,087)
Prepaid expenses and other current assets	3,337	3,337
Prepaid taxes	(372)	413
Assets held for sale		0
Total current assets	(2,640,936)	(2,506,547)
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Deferred tax assets	(75,509)	(76,524)
Notes receivable and other amounts due from consolidated subsidiaries	(3,474,221)	(3,473,153)
Other assets	(9,079,808)	(7,564,758)
Total assets	(15,270,474)	(13,620,982)
Current liabilities
Current borrowings	0	0
Accounts payable	0	0
Accounts payable to consolidated subsidiaries	(2,619,786)	(2,490,069)
Accrued expenses	0	0
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	0	0
Accrued interest	0	0
Income taxes payable	(970)	85
Other current liabilities	0	0
Total current liabilities	(2,620,756)	(2,489,984)
Long-term borrowings	0	0
Deferred tax liabilities	(75,509)	(76,524)
Pension and postretirement benefit liabilities	0	0
Noncurrent liability for uncertain tax positions	0	0
Notes payable and other amounts due to consolidated subsidiaries	(3,474,221)	(3,473,153)
Other liabilities	0	0
Total liabilities	(6,170,486)	(6,039,661)
Convertible notes - redeemable equity component		0
Mezzanine equity		0
Total shareholders' equity	(9,099,988)	(7,581,321)
Total liabilities and shareholders' equity	$ (15,270,474)	$ (13,620,982)

Condensed consolidating guara68

Condensed consolidating guarantor financial information - Cash Flows (Details) - USD ($) $ in Thousands	6 Months Ended
	Jul. 02, 2017	Jun. 26, 2016
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	$ 197,690	$ 181,488
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(36,833)	(19,535)
Proceeds from sale of assets	6,332	3,985
Payments for businesses and intangibles acquired, net of cash acquired	(993,459)	(3,117)
Net cash used in investing activities from continuing operations	(1,023,960)	(18,667)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	1,194,500	665,000
Reduction in borrowings	(228,273)	(656,479)
Debt extinguishment, issuance and amendment fees	(19,114)	(8,182)
Net proceeds from share based compensation plans and the related tax impacts	1,305	6,593
Payments for contingent consideration	(153)	(133)
Dividends paid	(30,590)	(28,998)
Intercompany transactions	0	0
Intercompany dividends paid	0
Net cash provided by (used in) financing activities from continuing operations	917,675	(22,199)
Cash flows from discontinued operations:
Net cash used in operating activities	(961)	(1,183)
Net cash used in discontinued operations	(961)	(1,183)
Effect of exchange rate changes on cash and cash equivalents	41,981	(1,315)
Net increase in cash and cash equivalents	132,425	138,124
Cash and cash equivalents at the beginning of the period	543,789	338,366
Cash and cash equivalents at the end of the period	676,214	476,490
Reportable Legal Entities | Parent Company
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(121,726)	(29,648)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(173)	(146)
Proceeds from sale of assets	0	0
Payments for businesses and intangibles acquired, net of cash acquired	(975,524)	0
Net cash used in investing activities from continuing operations	(975,697)	(146)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	1,194,500	665,000
Reduction in borrowings	(228,273)	(656,479)
Debt extinguishment, issuance and amendment fees	(19,114)	(8,182)
Net proceeds from share based compensation plans and the related tax impacts	1,305	6,593
Payments for contingent consideration	0	0
Dividends paid	(30,590)	(28,998)
Intercompany transactions	222,684	81,640
Intercompany dividends paid	0
Net cash provided by (used in) financing activities from continuing operations	1,140,512	59,574
Cash flows from discontinued operations:
Net cash used in operating activities	(961)	(1,183)
Net cash used in discontinued operations	(961)	(1,183)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	42,128	28,597
Cash and cash equivalents at the beginning of the period	14,571	21,612
Cash and cash equivalents at the end of the period	56,699	50,209
Reportable Legal Entities | Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	232,874	69,875
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(19,760)	(9,947)
Proceeds from sale of assets	0	20,642
Payments for businesses and intangibles acquired, net of cash acquired	0	0
Net cash used in investing activities from continuing operations	(19,760)	10,695
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0	0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	(153)	(133)
Dividends paid	0	0
Intercompany transactions	(203,029)	(79,348)
Intercompany dividends paid	0
Net cash provided by (used in) financing activities from continuing operations	(203,182)	(79,481)
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	9,932	1,089
Cash and cash equivalents at the beginning of the period	1,031	0
Cash and cash equivalents at the end of the period	10,963	1,089
Reportable Legal Entities | Non-Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	148,460	141,261
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(16,900)	(9,442)
Proceeds from sale of assets	6,332	1,251
Payments for businesses and intangibles acquired, net of cash acquired	(17,935)	(21,025)
Net cash used in investing activities from continuing operations	(28,503)	(29,216)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0	0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	0	0
Dividends paid	0	0
Intercompany transactions	(19,655)	(2,292)
Intercompany dividends paid	(61,918)
Net cash provided by (used in) financing activities from continuing operations	(81,573)	(2,292)
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	41,981	(1,315)
Net increase in cash and cash equivalents	80,365	108,438
Cash and cash equivalents at the beginning of the period	528,187	316,754
Cash and cash equivalents at the end of the period	608,552	425,192
Eliminations
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(61,918)	0
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	0	0
Proceeds from sale of assets	0	(17,908)
Payments for businesses and intangibles acquired, net of cash acquired	0	17,908
Net cash used in investing activities from continuing operations	0	0
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0	0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	0	0
Dividends paid	0	0
Intercompany transactions	0	0
Intercompany dividends paid	61,918
Net cash provided by (used in) financing activities from continuing operations	61,918	0
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents		0
Cash and cash equivalents at the beginning of the period	0	0
Cash and cash equivalents at the end of the period	$ 0	$ 0